fludarabine and busulfan

fludarabine has been researched along with busulfan in 529 studies

Research

Studies (529)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.19)	18.2507
2000's	148 (27.98)	29.6817
2010's	287 (54.25)	24.3611
2020's	93 (17.58)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP	1
Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G	1
Nagler, A; Naparstek, E; Or, R; Samuel, S; Slavin, S; Varadi, G	1
Nagler, A; Or, R; Slavin, S; Varadi, G	1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Kroschinsky, F; Naumann, R; Neubauer, A; Platzbecker, U; Plettig, R; Röllig, C; Schuler, U; Thiede, C	1
Aker, M; Brautbar, C; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G	1
Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ	1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Mohr, B; Platzbecker, U; Röllig, C; Schaich, M; Schäkel, U; Thiede, C	1
Ogura, M	1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Jenke, A; Lutterbeck, K; Oelschlagel, U; Platzbecker, U; Plettig, R; Röllig, C; Thiede, C	1
Classen, CF; Debatin, KM; Fairbanks, L; Friedrich, W; Hoffmann, GF; Schulz, AS; Sigl-Kraetzig, M; Simmonds, HA	1
Fujioka, T; Hirabayashi, N; Ikegame, K; Kawakami, M; Murakami, M; Ogawa, H; Soma, T; Sugiyama, H; Takahashi, R; Takimoto, T; Tamaki, H	1
Chi, HS; Kim, WK; Lee, JH; Lee, JS; Lee, KH	1
Akerstein, A; Engelhard, D; Gelfand, Y; Morecki, S; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G	1
Chizuka, A; Iijima, K; Iizuka, A; Kamijo, K; Kanai, S; Kanda, Y; Kawano, Y; Makimoto, A; Mineishi, S; Nakai, K; Niiya, H; Ohnishi, M; Ohnishi, T; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Ueda, K; Wakasugi, H; Yakushijin, K	1
Kashyap, A; Snowden, J	1
Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR	1
Bornhäuser, M; Ehninger, G; Hertenstein, B; Kiehl, M; Kröger, N; Martin, H; Runde, V; Sayer, HG; Schetelig, J; Schwerdtfeger, R; Siegert, W; Theuser, C	1
Bensinger, WI; Gooley, T; Maloney, DG; Sandmaier, BM; Storb, R; Weissinger, F	1
Brune, M; Ekman, T; Johansson, JE	1
Aschan, J; Barkholt, L; Brune, M; Hentschke, P; Mattsson, J; Ringdén, O; Stierner, U; Uzunel, M	1
Guo, K; Song, Z; Wu, B; Xiao, L; Yan, D; Yang, Y	1
Bargay, J; Brunet, S; Caballero, MD; Canals, C; Léon, A; Martino, R; Moraleda, JM; Pérez-Simón, JA; San Miguel, J; Sanz, GF; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A	1
Fukiya, E; Kimura, S; Kobayashi, Y; Kuroda, J; Murotani, Y; Ozawa, M; Terao, K; Yoshikawa, T	1
Andersson, BS; Brown, C; Chaudhry, A; Duggan, P; Glick, S; Gyonyor, E; Morris, D; Quinlan, D; Ruether, JD; Russell, JA; Stewart, D; Tran, HT	1
Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J	1
Belohradsky, BH; Blanche, S; Bordigoni, P; Cant, A; Di Bartolomeo, P; Fischer, A; Flood, T; Gungor, T; Landais, P; Müller, S; Nagler, A; Ozsahin, H; Passwell, JH; Porta, F; Seger, RA; Slavin, S; Wulffraat, N; Zintl, F	1
Ackerstein, A; Aker, M; Amar, A; Nagler, A; Naparstek, E; Or, R; Resnick, I; Samuel, S; Shapira, MY; Slavin, S	1
Basara, N; Fauser, AA; Guenzelmann, S; Kiehl, MG; Kraut, L; Roemer, E; Schmetzer, B	1
Ayuk, FA; Erttmann, R; Hansen, A; Hessling, J; Kordes, U; Kröger, N; Panse, J; Renges, H; Werner, M; Zabelina, T; Zander, AR	1
Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK	1
Beyer, J; Bornhäuser, M; Ehninger, G; Fauser, AA; Hensel, M; Ho, AD; Kiehl, M; Kienast, J; Kröger, N; Neubauer, A; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR	1
Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P	1
Ayash, L; Braun, T; Ferrara, JL; Hutchinson, R; Levine, JE; Ratanatharathorn, V; Reynolds, C; Silver, SM; Uberti, JP; Yanik, G	1
Flowers, ME; Leisenring, W; Maloney, DG; Maris, MB; Martin, PJ; Mielcarek, M; Sandmaier, BM; Storb, R	1
Anasetti, C; Appelbaum, FR; Bornhauser, M; Deeg, HJ; Ehninger, G; Hansen, J; Jenke, A; Martin, PJ; McDonald, GB; Nichols, WG; Radich, J; Schleyer, E; Slattery, JT; Storer, B; Thiede, C; Woolfrey, A	1
Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H	1
Beyer, J; Biersack, H; Bornhäuser, M; Ehninger, G; Kiehl, M; Kröger, N; Sayer, HG; Schäfer-Eckardt, K; Schwerdtfeger, R; Wandt, H; Zander, AR	1
Barker, JN; Blazar, BR; DeFor, TE; Miller, JS; Wagner, JE; Weisdorf, DJ	1
Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ	1
Brand, R; Corradini, P; Deliliers, GL; Dreger, P; Finke, J; Hansz, J; Martino, R; Michallet, M; Milligan, D; Niederwieser, D; Russell, N; Van Biezen, A	1
Beyer, J; Bornhauser, M; Ehninger, G; Fauser, AA; Held, TK; Hensel, M; Ho, AD; Hoffken, K; Kiehl, M; Kienast, J; Kroger, N; Neubauer, A; Sayer, HG; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR	1
Chi, HS; Choi, SJ; Kim, S; Kim, WK; Lee, JH; Lee, JL; Lee, JS; Lee, KH; Lee, YS; Park, CJ; Seol, M	1
Bardou, VJ; Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Braud, AC; Cahn, JY; Chabannon, C; Choufi, B; Faucher, C; Fleury, J; François, S; Gratecos, N; Gravis, G; Maraninchi, D; Michallet, M; Mohty, M; Sotto, JJ; Viens, P; Viret, F	1
Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D	1
Ackerstein, A; Bitan, M; Elad, S; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Zilberman, I	2
Fujioka, T; Ikegame, K; Kawakami, M; Kawase, I; Ogawa, H; Oji, Y; Oka, Y; Sugiyama, H; Tamaki, H; Tsuboi, A	1
Ogawa, H	1
Miyakoshi, S	1
Kusumi, E; Taniguchi, S	1
Chan, KW; Gomez Almaguer, D; Gordon, N; Mullen, CA; Tran, H; Worth, L	1
Beyer, J; Claviez, A; Dörffel, W; Dreger, P; Ehninger, G; Klingebiel, T; Nürnberger, W; Schmitz, N; Suttorp, M	1
Beelen, D; Bornhäuser, M; Ehninger, G; Fauser, AA; Held, TK; Kiehl, M; Kröger, N; Runde, V; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zabelina, T; Zander, A	1
Chizuka, A; Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Tajima, K; Takaue, Y; Taniguchi, S; Usubuchi, N	1
Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K	1
Devereux, S; Ho, AY; Kenyon, M; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE	1
Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X	1
Fujioka, T; Ishida, Y; Numaoka, H; Omori, S; Ono, Y	1
Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A	1
Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Coso, D; Damaj, G; Faucher, C; Gastaut, JA; Maraninchi, D; Michallet, AS; Michallet, M; Mohty, M; Perreau, V; Stoppa, AM; Tabrizi, R	1
Balashov, DN; Dyshlevaja, ZM; Maschan, AA; Rumiantsev, AG; Samochatova, EV; Shipicina, IP; Skorobogatova, EV; Skvortsova, YV; Trakhtman, PE	1
Arnold, R; Dörken, B; Heine, F; Le Coutre, P; Massenkeil, G; Nagy, M; Rosen, O	1
Bitan, M; Mador, N; Or, R; Resnick, IB; Saleh, N; Samuel, S; Schechter, E; Shapira, MY; Slavin, S; Weinberger, KM; Wolf, DG	1
Beilken, A; Das, A; Gal, A; Grigull, L; Luecke, T; Lukacs, Z; Rehe, K; Sander, A; Sauer, M; Schmid, H; Schrappe, M; Stanulla, M; Sykora, KW; Welte, K	1
Ayuk, F; Fehse, B; Fehse, N; Kröger, N; Kvasnicka, HM; Panse, J; Schieder, H; Stute, N; Thiele, J; Waschke, O; Zabelina, T; Zander, A	1
Diaconescu, R; Maloney, DG; Maris, MB; McSweeney, P; Parikh, CR; Sandmaier, BM; Schrier, RW; Sorror, ML; Storb, R; Storer, B	1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Jenke, A; Johne, C; Knoth, H; Schleyer, E	1
Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M	1
Briones, J; Brunet, S; Caballero, D; Cañizo, C; Clopés, A; Martino, R; Mateos, M; Moreno, E; Pérez-Simón, JA; Queraltó, JM; San Miguel, JF; Sierra, J; Sureda, A; Vazquez, L	1
Hara, S; Hayashi, S; Kamimura, T; Ogata, K; Suzumiya, J; Takamatsu, Y; Tamura, K; Yamauchi, K	1
Baumgart, J; Casper, J; Freund, M; Grobe, N; Hähling, D; Hartung, G; Hilgendorf, I; Junghanss, C; Kahl, C; Lück, A; Pichlmeier, U; Steiner, B; Wilhelm, S; Wolff, D	1
Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K	1
Abdul Hai, A; Ben-Harush, M; Bitan, M; Hershkovitz, E; Kapelushnik, J; Or, R; Resnick, IB; Schwartz, A; Shapira, MY; Slavin, S	1
Baxter-Lowe, LA; Cowan, M; Desantes, K; Englert, L; Horn, B; McMillan, A; Quinn, M	1
Andreani, M; Gaziev, J; Lucarelli, G; Polchi, P; Sodani, P	1
Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR	1
Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A	1
Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-Rangel, JD; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Rivas-Vera, S; Ruiz-Argüelles, GJ; Sobrevilla-Calvo, P; Vela-Ojeda, J	1
Ackerstein, A; Aker, M; Bitan, M; Elad, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S	1
Czepulkowski, B; Devereux, S; Duarte, RF; Ho, AY; Ingram, W; Kenyon, M; Lim, ZY; Mufti, GJ; Pagliuca, A; Pearce, L	1
Andreasson, B; Birgegård, G; Brune, M; Kutti, J; Lazarevic, V; LeBlanc, K; Malm, C; Merup, M; Nahi, H; Nilsson, L	1
Beri, R; Chen, HY; Chunduri, S; Dobogai, LC; Hoffman, R; Jessop, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y	1
Brychtova, Y; Dolezal, T; Doubek, M; Dvorakova, D; Horky, O; Koristek, Z; Krejci, M; Lengerova, M; Mayer, J; Pospisil, Z; Racil, Z; Vorlicek, J	1
Hori, A; Kami, M; Kobayashi, K; Komatsu, T; Kurita, N; Kusakabe, M; Matsumura, T; Murashige, N; Narimatsu, H; Tanaka, Y; Yoshimi, A; Yuji, K	1
Alyea, EP; Antin, JH; Cutler, C; DeAngelo, DJ; Ho, V; Kim, HT; Ritz, J; Soiffer, RJ; Stone, R	1
Alyea, EP; Antin, JH; Brown, JR; Cutler, C; Fisher, DC; Gribben, JG; Ho, V; Kim, HT; Lee, SJ; Li, S; Milford, EL; Ritz, J; Soiffer, RJ; Stephans, K	1
Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S	1
Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K	1
Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J	1
Bergeman, T; Bonin, M; Bornhauser, M; Ehninger, G; Illmer, T; Leopold, T; Pursche, S; Schleyer, E	1
Hanke, A; Lohse, P; Meissner, B; Rehe, K; Sauer, M; Sykora, KW; Welte, K; Zeidler, C	1
Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ	1
Andreesen, R; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Fauser, AA; Fietz, T; Freund, M; Hopfenmüller, W; Kanz, L; Keilholz, U; Knauf, W; Marinets, O; Ruutu, T; Schmidt-Hieber, M; Stuhler, G; Thiel, E; Trenschel, R; Uharek, L; Volin, L	1
Brown, C; Chaudhry, A; Larratt, L; Morris, D; Quinlan, D; Russell, JA; Stewart, D; Turner, AR	1
Ashida, T; Higashishiba, M; Kanamaru, A; Kawanishi, K; Mayama, T; Miyatake, J; Tatsumi, Y	1
Choi, Y; Keam, B; Kim, BK; Kim, I; Koo, NH; Lee, KH; Park, S; Yoo, KY; Yoon, SS	1
Chen, J; Li, JP; Zhang, T; Zhong, J; Zhu, KE	1
Alimoghaddam, K; Ashouri, A; Chahardovali, B; Evazi, MR; Ghaffari, SH; Ghavamzadeh, A; Iravani, M; Mousavi, SA; Samiee, S; Shamshiri, AR; Tavakoli, M	1
Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E	1
Akahane, D; Fukuda, T; Heike, Y; Kim, SW; Kusumoto, S; Mori, S; Morita-Hoshi, Y; Onishi, Y; Sugimoto, K; Takaue, Y; Tanosaki, R; Tobinai, K	1
Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S	1
Appelbaum, FR; Bedalov, A; Bryant, EM; Chang, C; Clurman, BE; Deeg, HJ; Flowers, ME; Hansen, JA; Nash, RA; Sanders, JE; Sandmaier, BM; Scott, BL; Shulman, HM; Storb, R; Storer, BE; Witherspoon, RP	1
Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, CH; Jaime-Pérez, JC; Martinez-González, O; Morales-Toquero, A; Ruiz-Argüelles, GJ; Salazar-Riojas, R; Tarín-Arzaga, LC	1
Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, SY; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS	1
Chiang, KY; Doering, CB; Gangadharan, B; Ide, LM; Spencer, HT	1
Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T	1
Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR	1
Barge, RM; Beaumont, F; Falkenburg, JH; Hoogendoorn, M; Jedema, I; Marijt, EW; van Luxemburg-Heijs, SA; Willemze, R	1
Chae, YS; Cho, GJ; Cho, YY; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Moon, JH; Shin, HJ; Sohn, SK; Yang, DH	1
Gesundheit, B; Resnick, IB	1
Hardan, I; Herscovici, C; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R	1
Bureo, E; Diaz de Heredia, C; Gonzalez-Vicent, M; Maldonado, MS; Martinez, A; Muñoz, A; Olivé, T; Sastre, A	1
Demidova, IA; Kut'ina, RM; Misiurin, AV; Ol'shanskaia, IuV; Parovichnikova, EN; Poreshina, LP; Savchenko, VG; Shpakova, AP	1
Abdul-Hai, A; Ackerstein, A; Aker, M; Amar, A; Bitan, M; Gesundheit, B; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, P	1
Bethge, W; Bornhäuser, M; de Witte, T; Kobbe, G; Kröger, N; Kvasnicka, HM; Schubert, J; Schwerdtfeger, R; Thiele, J; Zander, A	1
Chen, MH; Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hsu, HC; Lin, PC; Liu, JH	1
Hardan, I; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R	1
Bernal, MT; Besalduch, J; Brunet, MS; Caballero, D; Carrera, D; Ferra, C; Martin, J; Martino, R; Moraleda, JM; Nieto, JB; Perez-Simón, JA; Piñana, JL; Ribera, JM; Sampol, A; Sierra, J; Valcárcel, D; Vazquez, L	1
Azuma, T; Kami, M; Komatsu, T; Kusumi, E; Matsumura, T; Miura, Y	1
Fukuda, T; Heike, Y; Kato, R; Kim, S; Koido, K; Maruyama, D; Mori, S; Takaue, Y; Tanosaki, R; Teshima, T; Tobinai, K; Usui, E; Yamasaki, S	1
Andersson, BS; Bahlis, NJ; Brown, C; Chaudhry, MA; Geddes, M; Kangarloo, SB; Naveed, F; Quinlan, D; Russell, JA; Savoie, ML; Stewart, D; Storek, J	1
Esser, R; Kalaäoui, RE; Klingebiel, T; Kloess, S; Koehl, U; Kreuter, J; Lehrnbecher, T; Munkelt, D; Schubert, R; Schwabe, D; Wehner, S; Zimmermann, SY	1
Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Hurter, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y	1
Attal, M; Blaise, D; Boiron, JM; Bordigoni, P; Bourhis, JH; Chir, Z; Deconinck, E; Esperou, H; Le, QH; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Nicolini, F; Prébet, T; Renaud, M; Rio, B; Yakoub-Agha, I	1
Adachi, S; Kobayashi, C; Kojima, S; Kurosawa, H; Manabe, A; Nakahata, T; Nakazawa, Y; Nara, T; Ogawa, C; Ohtsuka, Y; Osugi, Y; Sako, M; Tokuyama, M; Yabe, H; Yabe, M; Yanagimachi, M	1
Chao, N; Chute, J; Gasparetto, C; Horwitz, ME; Long, G; McPherson, J; Morris, A; Rizzieri, D; Sullivan, K	1
Hamaki, T; Hori, A; Kami, M; Kanda, Y; Katayama, Y; Kishi, Y; Kobayashi, K; Mori, S; Murashige, N; Onishi, Y; Tajima, K; Takaue, Y; Tanosaki, R	1
Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D	1
Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, RB; Korbling, M; Pierre, B; Roberson, S; Russell, JA; Shpall, EJ; Thall, PF; Wang, X	1
Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J	1
Angelucci, E; Baronciani, D; Depau, C; Di Bartolomeo, P; Iori, AP; Mico, C; Pettinau, M; Pilo, F; Rambaldi, A; Santarone, S	1
Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duan, Q; Duggan, P; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N	1
Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ	1
Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ	1
Hara, J; Hashii, Y; Kusuki, S; Ohta, H; Ozono, K; Sakai, N; Takizawa, S; Taniike, M; Tokimasa, S	1
Benninghoff, U; Debatin, KM; Friedrich, W; Gatz, S; Hoenig, M; Schuetz, C; Schulz, A; Speth, F	1
Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M	1
Asano, S; Iseki, T; Kasahara, S; Kato, S; Konuma, T; Monma, F; Ooi, J; Sato, A; Takahashi, S; Tojo, A; Tomonari, A; Tsukada, N; Uchimaru, K	1
Barba, P; Briones, J; Brunet, S; Delgado, J; Martino, R; Moreno, E; Piñana, JL; Sierra, J; Sureda, A; Valcárcel, D; Vega, M	1
Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Ryu, SG; Seol, M; Shin, HJ	1
Karas, M; Koza, V; Steinerova, K; Vokurka, S	1
Asaka, M; Endo, T; Hashino, S; Imamura, M; Kahata, K; Koike, T; Kondo, T; Nishio, M; Okada, K; Onozawa, M; Ota, S; Sato, N; Shigematsu, A; Sugita, J; Takahata, M; Tanaka, J; Yamamoto, S; Yasumoto, A	1
Abidi, MH; Braun, TM; Ibrahim, RB; Khaled, YA; Krijanovski, OI; Levine, JE; Mineishi, S; Peres, E	1
Bordigoni, P; Cachin, F; Curtillet, C; David, A; Demeocq, F; Dore, E; Halle, P; Isfan, F; Kanold, J; Merlin, E; Michel, G; Paillard, C; Rochette, E; Rousseau, R; Salmon, A	1
Eyzaguirre-Zapata, R; Gómez-Almaguer, D; González-Carrillo, ML; Gutiérrez-Aguirre, CH; Gutiérrez-Riveroll, KI; Priesca-Marin, M; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ	1
Amdur, RJ; Buzzeo, MP; Cable, C; Jamieson, K; Khan, S; Leather, H; Moreb, J; Reddy, V; Schold, JD; Scornik, J; Wingard, JR	1
Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Mactal-Haaf, C; Mahmud, N; Peace, DJ; Quigley, JG; Rondelli, D; Shord, S; Sweiss, K	1
Andersson, BS; Champlin, RE; de Lima, M; Madden, T; Russell, JA; Thall, PF	1
Baurmann, H; Bethge, W; Bornhäuser, M; Brand, R; Burchert, A; Corradini, P; de Witte, TM; Dreger, P; Einsele, H; Holler, E; Kaufmann, M; Kobbe, G; Kröger, N; Kvasnicka, HM; Nagler, A; Niederwieser, D; Schubert, J; Schwerdtfeger, R; Stelljes, M; Thiele, J; Uharek, L; Wandt, H; Wulf, GG; Zabelina, T; Zander, AR	1
Andritsos, L; Bechtel, T; Benson, DM; Blum, W; Byrd, JC; Devine, SM; Elder, P; Garzon, R; Hamadani, M; Hofmeister, C; Klisovic, R; Krugh, D; Lin, T; Marcucci, G; O'Donnell, L; Penza, S; Phillips, G	1
Horiike, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M	1
Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Irish, W; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N	1
Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D	1
Aldridge, J; Alyea, EP; Antin, JH; Armand, P; Cutler, C; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ	1
Asaka, M; Endo, T; Hashino, S; Imamura, M; Ito, YM; Kahata, K; Koike, T; Kondo, T; Nishio, M; Okada, K; Onozawa, M; Shigematsu, A; Sugita, J; Takahata, M; Tanaka, J; Yamamoto, S	1
Andresen, S; Bolwell, B; Copelan, EA; Dean, R; Kalaycio, M; Mickelson, DM; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J	1
Asano-Mori, Y; Ishiwata, K; Masuoka, K; Matsuno, N; Miyakoshi, S; Ohashi, K; Ota, Y; Takagi, S; Takahashi, K; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, H	1
Aschan, J; Baumgart, J; Blau, IW; Casper, J; Freund, M; Giebel, S; Hilgendorf, I; Holowiecki, J; Knauf, W; Kröger, N; Mylius, HA; Pichlmeier, U; Ruutu, T; Schäfer-Eckart, K; Volin, L; Wandt, H; Wolff, D; Zander, AR	1
Andersson, BS; Valdez, BC	2
Appelbaum, FR; Douglas, JG; Mayadev, JS; Storb, R; Storer, BE	1
Almog, S; Gopher, A; Halkin, H; Hassoun, E; Kurnik, D; Loebstein, R; Nagler, A; Shimoni, A	1
Appay, V; Canellini, G; Laurent, J; Leyvraz, S; Papaioannou, A; Rimoldi, D; Romero, P; Rufer, N; Speiser, DE; Touvrey, C; Vicari, M; Voelter, V	1
Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE	1
Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW	1
Anasetti, C; Ayala, E; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kim, J; Perez, L; Perkins, J; Pidala, J	1
Au, MA; Boeckh, MJ; Chien, JW; Deeg, HJ; Milano, F	1
Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Garvin, JH; George, D; Harrison, L; Milone, MC; Morris, E; Satwani, P; Schwartz, J; Shaw, LM; Styczynski, J; Tallamy, B; van de Ven, C; Waxman, I	1
Eto, T; Fukuda, T; Hagihara, M; Hatanaka, K; Iida, H; Kanda, Y; Kasai, M; Kawano, F; Maeda, Y; Masuoka, K; Mori, T; Murata, M; Nagafuji, K; Nakagawa, H; Nakamae, M; Nishiwaki, K; Shirafuji, N; Takahashi, S; Takaue, Y; Taniguchi, S; Taniwaki, M; Togami, K; Uchida, T; Ueda, Y; Utsunomiya, A; Wake, A; Waki, F; Yakushiji, K; Yakushijin, K; Yamashita, T	1
Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; El Cheikh, J; Esterni, B; Farnault, L; Faucher, C; Fürst, S; Ladaique, P; Lemarie, C; Marchetti, N; Mohty, M; Prebet, T; Stoppa, AM; Vey, N	1
Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Komrokji, RS; Nishihori, T; Perkins, J; Pidala, J; Roman-Diaz, J	1
Artz, AS; Del Cerro, P; Godley, LA; Hart, J; Horowitz, S; Innocenti, F; Larson, RA; O'Donnell, PH; Odenike, OM; Pai, RK; Stock, W; Undevia, SD; Van Besien, K	1
Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Perez, L; Perkins, J; Pidala, J	1
Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC	1
Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL	1
Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; El Kourashy, S; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Williamson, T; Yang, M; Zacarias, N	1
Anderlini, P; Andersson, BS; Bashir, Q; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Fernandez-Vina, M; Giralt, S; Popat, U; Rodrigues, M; Sharma, M; Shpall, EJ; Wei, W	1
Anasetti, C; Ayala, E; Fancher, K; Fernandez, H; Field, T; Gardiner, JA; Kharfan-Dabaja, MA; Kim, J; Miller, S; Milone, MC; Perez, L; Perkins, J; Shaw, LM; Tate, C	1
Gao, W; Nimmagadda, S; Patel, P; Rondelli, D; Sweiss, K	1
Nagler, A; Shimoni, A	1
Bae, KS; Choi, Y; Han, SB; Hur, EH; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lim, HS; Lim, SN; Noh, GJ; Yun, SC	1
Balashov, D; Brooks, R; Maschan, A; Or, R; Resnick, IB; Revel-Vilk, S; Rheingold, L; Shapira, MY; Skorobogatova, E; Stein, J; Stepensky, P; Trakhtman, P; Weintraub, M	1
Anasetti, C; Ayala, E; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Perkins, J; Pidala, J; Roman-Diaz, J; Tate, C; Tomblyn, M	1
Bossuyt, X; Mariën, G; Uyttebroeck, A	1
de Lima, M; de Souza Santos, FP; Hamerschlak, N; Kerbauy, FR; Kutner, JM; Ribeiro, AA; Rodrigues, M; Sobrinho, JN; Torres, MA	1
Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J	1
Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W	1
Abraham, J; Andritsos, L; Benson, DM; Blum, W; Bunner, P; Craig, M; Cumpston, A; Devine, SM; Efebera, Y; Elder, P; Garzon, R; Gibson, L; Hamadani, M; Hofmeister, C; Leadmon, S; Penza, S; Phillips, GS; Remick, SC; Tse, W	1
Bautista, G; Cabrera, JR; Gonzalo-Daganzo, R; Regidor, C	1
Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S	1
Aimoto, M; Aimoto, R; Hayashi, Y; Hino, M; Inoue, A; Inoue, E; Koh, H; Koh, KR; Nakamae, H; Nakamae, M; Nakane, T; Nishimoto, M; Terada, Y; Yamane, T; Yoshimura, T	1
Allen, JC; Chowbay, B; Diong, CP; Goh, YT; Hwang, WY; Linn, YC; Loh, SM; Wong, AM	1
Bae, SH; Choi, SJ; Hyun, MS; Jeon, M; Joo, YD; Kang, MJ; Kang, YA; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Lee, YS; Park, JH; Ryoo, HM; Seol, M; Yun, SC	1
Ayari, S; Blin, N; Brissot, E; Cahu, X; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Harousseau, JL; Le Gouill, S; Mahe, B; Malard, F; Miplied, N; Mohty, M; Moreau, P	1
Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR	1
Alimoghaddam, K; Ghavamzadeh, A; Hadjibabaie, M; Hayatshahi, A; Iravani, M; Javadi, MR; Khoee, SH; Mansouri, A; Shamshiri, AR	1
Abdullah, A; Ho, AY; Kenyon, M; Krishnamurthy, P; Lea, N; Lim, ZY; Marsh, J; Mufti, GJ; Nagi, W; Pagliuca, A; Potter, V; Reiff-Zall, L; Tindell, V	1
Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC	1
Blough, DK; Deeg, HJ; McCune, JS; McDonald, GB; O'Donnell, PV; Pawlikowski, MA; Rezvani, A; Yeh, RF	1
Brychtova, Y; Doubek, M; Dvorakova, D; Horky, O; Krejci, M; Lengerova, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M	1
Boiron, JM; Bouabdallah, K; Coiffard, J; Dilhuydy, MS; Lafarge, X; Leguay, T; Marit, G; Melot, C; Milpied, N; Pigneux, A; Schmitt, A; Tabrizi, R; Vigouroux, S	1
Bahlis, NJ; Carlson, L; Duan, Q; Duggan, P; Hasegawa, W; Russell, JA; Stewart, DA; Voralia, M	1
Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Della-Latta, P; Freedman, J; Garvin, JH; George, D; Geyer, MB; Harrison, L; Jacobson, JS; Moore, V; Morris, E; Satwani, P; Schwartz, J; van de Ven, C	1
Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F	1
Eshkar-Sebban, L; Gellman, YN; Lytton, SD; Nagler, A; Naor, D; Or, R; Refaeli, E; Rosenblum, N; Shimoni, A; Shimony, O; Stanevsky, A; Yerushalmi, R	1
Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H	1
Anne, N; Eeva, J; Heli, U; Liisa, V; Tapani, R	1
Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ	1
Baumgart, J; Beelen, DW; Blau, I; Bornhaeuser, M; Casper, J; Einsele, H; Freund, M; Giebel, S; Holowiecki, J; Kruzel, T; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Ruutu, T; Schaefer-Eckart, K; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Wandt, H; Zander, AR	1
Anasetti, C; Ayala, E; Fernandez, HF; Field, TL; Kharfan-Dabaja, MA; Kim, J; Perez, LE; Perkins, JB; Pidala, JA; Sullivan, DM; Tomblyn, MR	1
Artz, AS; Hart, J; O'Donnell, PH; Pai, RK; van Besien, K	1
Elashoff, D; Giannoni, F; Kahl, CA; Kohn, DB; Lee, CC; Louie, SG; Martinez, M; Sumiyoshi, T; Tarantal, AF; Wherley, J	1
Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El Cheikh, J; Esterni, B; Etienne, A; Faucher, C; Fürst, S; Prebet, T; Vey, N	1
Barrenetxea, C; Boluda, JC; de Heredia, CD; Ferrá, C; González, M; Martín, C; Martinez, AM; Sanz, GF; Sanz, J; Sanz, MA; Serrano, D; Solano, C	1
Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R	1
Faber, E; Hubacek, J; Indrak, K; Jarosova, M; Katrincsakova, B; Kurfurst, P; Pikalova, Z; Raida, L; Rusinakova, Z; Skoumalova, I; Tucek, P; Vondrakova, J	1
Chae, YS; Choi, JY; Kang, BW; Kim, JG; Kim, YK; Lee, SJ; Lee, YJ; Moon, JH; Seo, JW; Shin, HC; Sohn, SK; Suh, JS	1
Baxter-Lowe, LA; Cowan, MJ; Dvorak, CC; Horn, B; Law, J; Long-Boyle, JR; Musick, L	1
Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M	1
Ariga, T; Hershfield, MS; Imai, K; Kanegane, H; Miyawaki, T; Nomura, K; Santisteban, I; Taneichi, H; Wada, T; Yachie, A	1
Bahlis, N; Brown, C; Chaudhry, A; Daly, A; Duggan, P; Geddes, M; Russell, J; Savoie, ML; Shafey, M; Stewart, D; Storek, J; Turner, AR	1
Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R	1
Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Esterni, B; Fürst, S; Granata, A; Oudin, C; Vey, N	1
Duszeńko, E; Haus, O; Kałwak, K; Musiał, J; Ussowicz, M	1
Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Kim, SD; Lee, GW; Lee, JH; Lee, KH; Lee, WS; Min, YJ; Park, JH; Ryoo, HM	1
Galaup, A; Paci, A	1
Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK	1
Bolognia, JL; Cooper, DL; Parker, TL; Seropian, SE	1
Anderlini, P; Bassett, R; Champlin, R; de Lima, M; Ganesan, P; Giralt, S; Kebriaei, P; Khouri, I; Parmar, S; Rondon, G; Thall, P	1
Blaise, D; Castagna, L	1
Fan, ZP; Huang, F; Jiang, QL; Liu, H; Liu, QF; Sun, J; Wu, MQ; Yu, GP; Zhang, X; Zhou, HS	1
Ayari, S; Blin, N; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lestang, E; Mahe, B; Mohty, M; Moreau, P; Planche, L; Roland, V; Tessoulin, B	1
Fan, Z; Guo, X; Huang, F; Li, Y; Liu, H; Liu, Q; Nie, D; Song, Z; Sun, J; Tu, S; Xiao, Y; Yu, G; Zhai, X; Zhang, Y; Zhou, H	1
Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Geyer, MB; Harrison, L; Jin, Z; Morris, E; Radhakrishnan, K	1
Abdel-Rahman, F; Abu-Jazar, H; Al-Zaben, A; Frangoul, H; Ghatasheh, L; Hammada, T; Hussein, AA; Najjar, R; Natsheh, A; Sharma, S	1
Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM	1
Bene, MC; Blin, N; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lode, L; Loirat, M; Mahe, B; Malard, F; Mohr, C; Mohty, M; Moreau, P; Peterlin, P; Planche, L	1
Alyea, EP; Antin, JH; Armand, P; Attar, EC; Ballen, KK; Chen, YB; Coughlin, E; Cutler, C; Dey, BR; Ho, VT; Kennedy, KF; Koreth, J; McAfee, SL; Soiffer, RJ; Spitzer, TR	1
Boyer, J; Frey, NV; Goldstein, SC; Hexner, EO; June, CH; Kumar, AJ; Levine, BL; Loren, AW; Luger, SM; Porter, DL; Reshef, R; Smith, J; Stadtmauer, EA	1
Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Issaragrisil, S; Jetsrisuparb, A; Pakakasama, S; Rujkijyanont, P; Sirachainan, N; Sirireung, S; Songdej, D; Srisala, S; Sruamsiri, R; Ungkanont, A	1
Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U	1
Azik, F; Emir, S; Erdem, AY; Isik, P; Metin, A; Tavil, B; Tunc, B; Uckan, D	1
Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Lemarie, C; Oudin, C; Saillard, C; Signori, A	1
Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Kangarloo, SB; Larratt, L; Russell, JA; Savoie, ML; Shafey, M; Stewart, DA; Storek, J; Turner, AR; Williamson, T; Yang, M; Yue, P; Zacarias, N	1
Colturato, VA; de Castro, FA; Lanchote, VL; Simões, BP; Voltarelli, JC	1
Anasetti, C; Ayala, E; Betts, B; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kunter, G; Locke, F; Nieder, M; Nishihori, T; Ochoa-Bayona, JL; Perez, L; Perkins, JB; Pidala, J; Tomblyn, M	1
Arakawa, T; Hino, M; Koh, H; Nakamae, H; Nakane, T; Nishimoto, M; Ohsawa, M; Watanabe, K	1
Chen, BA; Ding, BH; Ding, JH; Li, YF; Qian, J; Yu, ZP	1
Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X	1
Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Coso, D; Crocchiolo, R; D'Incan, E; Devillier, R; El-Cheikh, J; Etienne, A; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Picard, C; Schiano, JM; Stoppa, AM; Vey, N	1
Andersson, BS; Champlin, RE; Corn, P; Dominguez, JR; Li, Y; Song, G; Valdez, BC	1
Ahmad, I; Albert, MH; Belohradsky, BH; Bredius, R; Fasth, A; Fernandes, JF; Fischer, A; Gaspar, HB; Gennery, A; Gruhn, B; Güngör, T; Haddad, E; Hassan, M; Hough, R; Kentouche, K; Lachance, S; Moshous, D; Rentsch, K; Resnick, IB; Schanz, U; Schlegel, PG; Seger, R; Shaw, PJ; Slatter, M; Stepensky, P; Stussi, G; Teira, P; Telles da Cunha, JM; Vermont, C; Veys, P	1
Huang, XJ; Ji, Y; Liu, DH; Liu, KY; Sun, YQ; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH; Zhang, YY	1
Bartelink, IH; Bierings, MB; Boelens, JJ; de Wildt, A; Gerhardt, CE; Lindemans, CA; van Maarseveen, EM; van Reij, EM; Versluys, B	1
Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Crocchiolo, R; Devillier, R; El-Cheikh, J; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Mohty, B; Oudin, C; Rey, J; Stoppa, AM; Vey, N	1
Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP	1
Craig, M; Cumpston, A; Evans, K; Goff, L; Hamadani, M; Kanate, AS; Leadmon, S; Rauenzahn, S; Truong, Q; Wen, S; Zhang, J	1
Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N	1
Bo, J; Cai, B; Gao, C; Han, X; Huang, W; Jing, Y; Li, H; Luo, L; Wang, Q; Yu, L; Zhang, L; Zhao, Y; Zhu, H	1
Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B	1
Chen, H; Fu, HX; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Tang, FF; Wang, FR; Wang, Y; Xu, LP	1
Choi, I; Jang, YJ; Jeon, M; Jung, SJ; Kang, M; Kang, YA; Kim, DY; Kim, H; Kim, HJ; Lee, JH; Lee, JL; Lee, KH; Lee, YS; Park, SY; Seol, M; Yeom, YI; Yoon, SR; Yun, SC	1
Chambellan, A; Chevallier, P; Delasalle, B; Delaunay, J; Dirou, S; Germaud, P; Guillaume, T; Lemarchand, P; Malard, F; Mohty, M; Moreau, P	1
Dahllöf, G; Heimdahl, A; Legert, KG; Remberger, M; Ringdén, O	1
Chantepie, SP; Gac, AC; Reman, O	1
Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY	1
Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Garvin, J; George, D; Geyer, MB; Hawks, R; Jin, Z; Lee, MT; Licursi, M; Morris, E; Radhakrishnan, K; Satwani, P; Schwartz, J; Smilow, E; Zuckerman, W	1
Assanelli, A; Battaglia, M; Bernardi, M; Bondanza, A; Bonini, C; Bordignon, C; Carbone, MR; Carrabba, M; Ciceri, F; Clerici, D; Corti, C; Crocchiolo, R; Crotta, A; Crucitti, L; Ferraro, A; Fleischhauer, K; Forcina, A; Giglio, F; Guggiari, E; Locatelli, F; Lorusso, A; Lunghi, F; Marcatti, M; Marktel, S; Mastaglio, S; Messina, C; Noviello, M; Olek, S; Oliveira, G; Patriarca, F; Peccatori, J; Roncarolo, MG; Rossini, S; Stanghellini, MT; Tassara, M; Vago, L; Zecca, M	1
Alam, N; Atenafu, EG; Gupta, V; Kim, DH; Kuruvilla, J; Lipton, JH; Messner, HA; Seftel, M; Shanavas, M; Uhm, J	1
Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S	1
Alati, C; Console, G; Cuzzola, M; Dattola, A; Fedele, R; Gallo, GA; Irrera, G; Martinello, T; Martino, M; Messina, G; Molica, S; Moscato, T; Pontari, A; Princi, D; Ronco, F	1
Abedin, S; Choi, S; Couriel, DR; Levine, JE; Peres, E; Yanik, G	1
Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Issaragrisil, S; Jetsrisuparb, A; Meekaewkunchorn, A; Mekjaruskul, P; Pakakasama, S; Pongtanakul, B; Rujkijyanont, P; Sanpakit, K; Sirachainan, N; Songdej, D; Sruamsiri, R; Ungkanont, A	1
Gupta, V; Hamad, N; Kim, DD; Kuruvilla, J; Lipton, JH; Messner, HA; Michelis, FV; Seftel, M; Shanavas, M; Uhm, J	1
Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC	1
Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C	1
Chen, T; Du, Q; Huang, Y; Lin, X; Lu, Z; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B	1
Bunin, N; Heimall, J; Morsheimer, M; Oshrine, B	1
Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE	1
Andersson, BS; Champlin, RE; de Lima, MJ; Furlong, T; Jones, RJ; Kanakry, CG; Luznik, L; Medeot, M; Mielcarek, M; O'Donnell, PV; Thall, PF; Wei, W	1
Blaise, D; Chevallier, P; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Le Gouill, S; Malard, F; Milpied, N; Mohty, M; Moreau, P; Tabrizi, R; Vigouroux, S	1
Dinur-Schejter, Y; Erlich, O; Gorelik, N; Krauss, AC; Porat, I; Stein, J; Stepensky, P; Weintraub, M; Yahel, A; Zaidman, I	1
Chen, XC; Huang, XO; Li, JJ; Liu, T; Liu, ZG; Lu, ZP; Tang, Y	1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH	1
Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S	1
Afanasyev, B; Baron, F; Deconinck, E; Jindra, P; Labopin, M; Mohty, M; Nagler, A; Peniket, A; Sanz, MA	1
Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N	1
Choi, YS; Jeon, YW; Kim, DY; Kim, HJ; Kim, JH; Kim, YJ; Lee, JH; Lee, JW; Lee, KH; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH	1
Assanelli, A; Bernardi, M; Carrabba, M; Ciceri, F; Claudiani, S; Corti, C; De Freitas, T; Giglio, F; Guggiari, E; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Peccatori, J; Piemontese, S	1
Guilcher, GM; Lewis, VA; Moorjani, R; Truong, TH	1
Inagaki, J; Kakuda, H; Kudo, K; Kurosawa, H; Manabe, A; Ohtsuka, Y; Sakashita, K; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N	1
Adachi, S; Atsuta, Y; Goto, H; Hasegawa, D; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kawa, K; Koh, K; Kudo, K; Okamoto, Y; Yabe, H	1
Chen, H; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH; Zhang, YY	1
Abraham, A; Benton, M; Brown, C; Chiang, KY; Dioguardi, JL; Grizzle, A; Haight, A; Hale, G; Horan, JT; Kanter, J; Kasow, KA; Nieder, M; Shelman, C	1
Araoka, H; Asano-Mori, Y; Ikebe, T; Ishiwata, K; Izutsu, K; Kon, A; Makino, S; Masuoka, K; Matsuno, N; Nakano, N; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A	1
Aljurf, MD; Arat, M; Bader, P; Boelens, JJ; Duarte, R; Faraci, M; Lawitschka, A; Peters, C; Socie, G; Tichelli, A; Veys, P; Wachowiak, J; Yaniv, I	1
Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C	1
Bollard, C; Cuellar-Rodriguez, J; Freeman, AF; Gea-Banacloche, J; Grossman, J; Hickstein, DD; Holland, SM; Kong, HH; Moutsopoulos, N; Murdock, H; Parta, M; Shah, N; Stone, K; Su, H	1
Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L	1
Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B	1
Ahmed, S; Al Atrash, G; Alousi, AM; Andersson, B; Brammer, JE; Champlin, RE; Chen, J; Ciurea, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Nieto, Y; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saliba, RM; Shah, N; Shpall, EJ	1
Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC	1
Aldenhoven, M; Bierings, MB; Boelens, JJ; Bonney, D; Borrill, RE; Coussons, M; Jones, SA; Mercer, J; van der Ploeg, AT; van Hasselt, PM; Versluys, B; Wijburg, FA; Wynn, RF	1
Bixby, D; Braun, T; Choi, S; Churay, T; Couriel, DR; Frame, D; Goldstein, SC; Harris, A; Kitko, C; Levine, J; Li, Y; Magenau, JM; Mineishi, S; Parkin, B; Pawarode, A; Reddy, P; Riwes, MM; Yanik, G	1
Champagne, C; Farrant, P; Taylor, M	1
Bashey, A; Brown, SL; Connor, K; Hilton, S; Holland, HK; Morris, LE; Sanacore, M; Solomon, SR; Zhang, X	1
Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ	1
Chen, P; Chen, Y; Hu, W; Li, N; Li, X; Yang, W	1
Alousi, A; Anderlini, P; Andreeff, M; Benton, CB; Champlin, R; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Kebriaei, P; Konopleva, M; Lu, H; McMullin, B; Nieto, Y; Parmar, S; Popat, U; Qiao, W; Rondon, G; Schober, W; Shpall, E; Thall, PF; Wang, RY; Woodworth, G; Zeng, Z	1
Fan, X; Hu, J; Tang, W; Wang, L	2
Boyraz, MS; Çağdaş, D; Güçer, Ş; Tezcan, İ; Uçkan Çetinkaya, D; Ünal, Ş	1
Daimon, T; Ikegame, K; Ishii, S; Kaida, K; Kanda, Y; Kaya, H; Kodera, Y; Kurokawa, T; Maeda, Y; Ogawa, H; Okada, M; Okumura, H; Shimizu, H; Tamaki, H; Taniguchi, K; Taniguchi, S; Ueda, Y; Yoshida, T; Yoshihara, S	1
Deng, L; Guo, KY; He, YZ; Huang, YX; Lin, X; Long, H; Lu, ZG; Song, CY; Tu, SF; Wu, BY; Xu, JH	1
Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G	1
Bazarbachi, A; Beelen, D; Bermudez, A; Blaise, D; Fegueux, N; Hamladji, RM; Kharfan-Dabaja, MA; Kroeger, N; Labopin, M; Lioure, B; Mohty, M; Nagler, A; Or, R; Socie, G; Veelken, H	1
Abramson, J; Antin, JH; Armand, P; Barnes, J; Brown, J; Chen, YB; Cutler, C; Del Rio, C; Driscoll, J; El-Jawahri, A; Fisher, DC; Ho, VT; Hochberg, E; Jacobsen, E; Li, S; McAfee, S; Soiffer, R; Spitzer, TR; Takvorian, R	1
Asma, S; Boga, C; Kasar, M; Kozanoglu, I; Maytalman, E; Ozdogu, H; Yeral, M	1
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Chammas, MJ; Cutler, CS; Glotzbecker, B; Ho, VT; Kim, HT; Koreth, J; Lange, PB; Nikiforow, S; Reynolds, CG; Ritz, J; Soiffer, RJ	1
Boga, C; Kasar, M; Kozanoglu, I; Ozdogu, H; Sariturk, C; Yeral, M	1
Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J	1
Baxter-Lowe, L; Bruckner, A; Cairo, MS; Chen, M; Christiano, AM; Fabricatore, S; Geyer, MB; Giller, R; Harel, S; Kandel, J; Kiuru, M; LeBoeuf, N; McGrath, J; Morel, KD; Radhakrishnan, K; Uitto, J; Umegaki, N; Woodley, D	1
Alatrash, G; Andersson, BS; Champlin, R; Charafeddine, Y; Chen, J; Ciurea, S; Kebriaei, P; Lee, HC; Medeiros, LJ; Oran, B; Popat, U; Rondon, G; Saliba, RM; Shpall, E	1
Iida, S; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Masaki, A; Masuda, A; Narita, T; Ri, M; Totani, H; Yoshida, T	1
Armistead, P; Chung, Y; Coghill, J; Comeau, T; Gabriel, D; Ivanova, A; Rao, K; Sarantopoulos, S; Serody, J; Shea, TC; Sheets, J; Walko, C; Wood, W	1
Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S	1
Avigdor, A; Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R	1
Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q	1
Boztug, H; Cant, A; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M	1
Bruce, AJ; Chaudhry, HM; Hashmi, SK; Hogan, WJ; Kremers, WK; Litzow, MR; Patnaik, MS; Phillips, GL; Wolf, RC	1
Bethge, WA; Buechele, C; Faul, C; Federmann, B; Helwig, A; Kanz, L; Schmohl, J; Schneidawind, D; Vogel, W	1
Alessandrino, EP; Arcese, W; Bacigalupo, A; Boschini, C; Bosi, A; Bruno, B; Busca, A; Carella, AM; Cavattoni, I; Chiusolo, P; Corradini, P; Grassi, A; Guidi, S; Marfisi, RM; Marotta, G; Masciulli, A; Micò, MC; Milone, G; Montanari, M; Mordini, N; Nagler, A; Oldani, E; Pastore, D; Patriarca, F; Pini, M; Raimondi, R; Rambaldi, A; Risitano, AM; Russo, D; Santarone, S; Saporiti, G; Scimè, R; Terruzzi, E; Torelli, GF	1
Byrne, JA; Earl, JW; Fraser, CJ; Koyyalamudi, SR; Kuzhiumparambil, U; Nath, CE; O'Brien, TA; Shaw, PJ	1
Avivi, I; Ben-Barouch, S; Cohen, O; Ram, R; Vidal, L	1
Alyea, EP; Blum, W; Carter, S; Champlin, RE; Chen, YB; Devine, SM; Giralt, S; Hars, V; Horowitz, MM; Hsu, JW; Larson, RA; Linker, C; Mulkey, F; Owzar, K; Shea, TC; Sibley, AB; Slack, J; Soiffer, RJ; Stone, RM; Vij, R	1
Fuji, S; Fukuda, T; Hagiwara, S; Hatanaka, K; Hidaka, M; Ito, T; Kim, SW; Kurosawa, S; Nakamae, H; Ohashi, K; Takami, A; Yamaguchi, T; Yamashita, T; Yano, S	1
Bhargava, S; Chakrabarti, A; Chakrabarti, S; Chatterjee, S; Jaiswal, SR; O'Donnell, P; Ray, K	1
Biemond, BJ; Cornelissen, JJ; Graux, C; Hazenberg, CL; Kuball, J; Löwenberg, B; Maertens, J; Ossenkoppele, G; Pabst, T; Passweg, JR; Schouten, HC; Theobald, M; van Putten, WL; Vellenga, E; Versluis, J	1
Du, H; Jing, Y; Lu, W; Luan, Z; Tang, X; Wu, N; Xu, S; Zhang, B	1
Chang, W; Chen, F; Fu, C; Jin, Z; Ma, X; Miao, M; Qiu, H; Ruan, C; Sun, A; Tang, X; Wu, D; Xue, S	1
Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE	1
Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Cooney-Qualter, E; Fabricatore, S; Harrison, L; Kletzel, M; Luisi, P; Militano, O; Morris, E; Ricci, A; Roy, S; van de Ven, C; Wolownik, K; Zahler, S	1
Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ	1
Ding, K; Geng, L; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zhang, L; Zhang, X; Zheng, C; Zhu, X	1
Bermúdez, A; Caballero, MD; Cabrero, M; Conde, E; De La Serna, J; Gómez, V; Lahuerta, JJ; Moraleda, JM; Perez, SG; Sanz, G; Sanz, J; Serrano, D; Vallejo, C	1
Alchalby, H; Ayuk, F; Cassinat, B; Christopeit, M; Kröger, N; Peffault de Latour, R; Porcher, R; Robin, M; Sicre de Fontbrune, F; Socié, G; Wolschke, C; Zabelina, T	1
Hong, DS; Ji, YS; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MS; Min, CW; Park, SK; Won, JH; Yun, J	1
Choi, EJ; Jeon, M; Kang, YA; Kim, DY; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M	1
Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ	1
Artz, A; Bredeson, C; Burkart, J; DiPersio, J; Fernandez, HF; Kamishohara, M; Le-Rademacher, J; Mehta, J; Mineishi, S; Nakamura, Y; Pasquini, MC; Ratanatharathorn, V; Sobecks, R; Zhu, X	1
Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC	1
Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Li, Y; Liu, Y; Murray, D; Nieto, Y; Teo, EC; Valdez, BC	1
Baxter-Lowe, LA; Cairo, MS; Dalal, R; Dozor, AJ; Fabricatore, S; Harrison, L; Jin, Z; Majzner, R; Morris, E; Sandoval, C; van de Ven, C; Wolownik, K	1
Asano-Mori, Y; Ishiwata, K; Izutsu, K; Kageyama, K; Kaji, D; Makino, S; Masuoka, K; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A; Yuasa, M	1
Andou, T; Fujisawa, S; Hagihara, M; Ishii, Y; Itabashi, M; Koyama, S; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W	1
Chinratanalab, W; Engelhardt, BG; Goodman, SA; Greer, JP; Jagasia, M; Kassim, AA; Kennedy, VE; Savani, BN; Sengsayadeth, S	1
Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL	1
Katsanis, E; Kopp, LM; Pelayo-Katsanis, L; Sapp, LN; Whitney, K; Zeng, Y	1
Antin, JH; Armand, P; Caballero, D; Cabrero, M; Esquirol, A; Kekre, N; Lopez-Corral, L; Marquez-Malaver, FJ; Martino, R; Pérez-Simon, JA; Piñana, J; Soiffer, RJ; Solano, C; Terol, MJ	1
Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY	1
Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z	1
Bittenbring, J; Ganser, A; Hallek, M; Huynh, A; Kröger, N; Labopin, M; Malard, F; Michallet, M; Mohty, M; Nagler, A; Savani, BN; Schmid, C; Stuhler, G; Tischer, J	1
Crazzolara, R; Haas, OA; Kager, L; Kropshofer, G; Matthes-Martin, S	1
Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y	1
Abounader, DM; Andresen, S; Bolwell, BJ; Dean, R; Ferraro, C; Gerds, AT; Hamilton, BK; Hanna, R; Hill, BT; Kalaycio, M; Liu, H; Majhail, NS; Mustafa Ali, M; Pohlman, B; Rybicki, LA; Sobecks, RM; Starn, J; Winslow, V; Yurch, MA	1
Blaise, D; D'Aveni-Piney, M; Daguindeau, E; Diez-Martin, JL; Hamladji, RM; Irrera, G; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Richard, C; Rubio, MT; Santarone, S; Sanz, MA; Savani, BN; Yakoub-Agha, I; Yeshurun, M	1
Baker, KS; Boulad, F; Davies, SM; Guinan, E; Kernan, NA; Lane, A; Leemhuis, T; Lehmann, L; Margolis, D; Mehta, PA; Myers, K; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Williams, DA	1
Daly, A; Geddes, M; Lam, W; Li, H; Storek, J	1
Ali, M; Courtney, S; Krueger, J; Lowry, J; Ramzan, M; Schechter Finkelstein, T	1
Ball, LM; Bresters, D; Fiocco, M; Louwerens, M; van Doorn, R; Wanders, DCM	1
Alyea, EP; Bashey, A; Deeg, HJ; Devine, SM; Fernandez, HF; Geller, NL; Giralt, S; Hamadani, M; Horowitz, MM; Horwitz, ME; Le-Rademacher, J; Leifer, E; Logan, BR; Maziarz, RT; Mendizabal, AM; Pasquini, MC; Porter, DL; Scott, BL; Warlick, ED; Wu, J	1
Ashida, A; Ashida, T; Enomoto, A; Hamada, S; Matsunaga, K; Miki, H; Mukai, T; Torihata, S; Uchihashi, T; Yasumoto, M; Yasutake, N	1
Boelens, JJ; Egas, AC; Langenhorst, JB; Punt, AM; van Kesteren, C; van Maarseveen, EM	1
Afanasyev, B; Bethge, W; Brand, R; de Witte, T; Deliliers, GL; Dreger, P; Franke, GN; Guidi, S; Günther, A; Heim, D; Hübel, K; Iacobelli, S; Kobbe, G; Kröger, N; Onida, F; Pini, M; Platzbecker, U; Poiré, X; Robin, M; Scheid, C; Stelljes, M; Uddin, R; van Os, M; Volin, L; Weber, T	1
Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP	2
Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC	1
Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R	1
Barker, JN; Boulad, F; Castro-Malaspina, H; Fuller, K; Hilden, PD; Hsu, KC; Jakubowski, AA; Kernan, NA; Koehne, G; O'Reilly, RJ; Papadopoulos, EB; Perales, MA; Prockop, SE; Scaradavou, A; Spitzer, B; van den Brink, MR; Young, JW	1
Delaney, C; Gammill, H; Kanaan, SB; Milano, F; Nelson, JL; Oliver, DC	1
Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK	1
Björklund, A; Garming-Legert, K; Hassan, M; Ljungman, P; Mattsson, J; Remberger, M; Serafi, IE; Sundin, M; Törlen, J	1
Aoki, J; Atsuta, Y; Eto, T; Fukuda, T; Ichinohe, T; Ishiyama, K; Iwato, K; Kahata, K; Kako, S; Kanamori, H; Kanda, Y; Kawamura, K; Kondo, T; Mizuta, S; Ozawa, Y; Sawa, M; Uchida, N; Yano, S	1
Bay, JO; Blaise, D; Bulabois, CE; Ceballos, P; Chantepie, S; Charbonnier, A; Chevallier, P; Contentin, N; Cornillon, J; Daguindau, E; Deconinck, E; Labopin, M; Le Bourgeois, A; Maillard, N; Marçais, A; Marchand, T; Mercier, M; Mohty, M; N'Guyen, S; Peffault de Latour, R; Rorhlich, PS; Turlure, P; Vigouroux, S; Yakoub-Agha, I	1
Bell, AD; Cheng, JC; Gutierrez, L; Karras, NA; Pawlowska, AB; Rosenthal, J; Sun, W; Wang, LD	1
Ahmed, S; Ahn, KW; Armand, P; Epperla, N; Fenske, TS; Hamadani, M; Jagasia, M; Jaglowski, S; Kenkre, VP; Savani, B; Shah, NN; Smith, SM; Sureda, A	1
Abu-Arja, R; Guilcher, GMT; Pai, V; Rangarajan, HG; Soni, S	1
Ahn, JS; Choi, Y; Lee, HS; Lee, JH; Lee, JO; Lee, WS; Moon, JH; Park, S; Shin, DY; Shin, HJ; Song, IC; Yoon, SS	1
Abd Hamid, IJ; Abinun, M; Amrolia, P; Cant, AJ; Chiesa, R; Elfeky, R; Flood, T; Gaspar, HB; Gennery, AR; Hambleton, S; Nademi, Z; Pearce, MS; Qasim, W; Rao, K; Slatter, MA; Veys, P; Worth, A	1
Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I	1
Algeri, M; Aricò, M; Basso, G; Caniglia, M; Cesaro, S; Di Bartolomeo, P; Fagioli, F; Favre, C; Giardino, S; Locatelli, F; Marzollo, A; Merli, P; Messina, C; Pillon, M; Porta, F; Prete, A; Rabusin, M; Ripaldi, M; Rovelli, A; Saglio, F; Sieni, E; Zecca, M; Ziino, O	1
Avni, B; Grisariu, S; Hussein, F; Lokshin, E; NaserEddin, A; Oron, HC; Shadur, B; Stepensky, P; Zaidman, I	1
Asma, S; Aytan, P; Boga, C; Gereklioglu, C; Kozanoglu, I; Maytalman, E; Ozdogu, H; Sariturk, C; Yeral, M	1
Cairo, MS; Cooper, T; Dang, H; Dvorak, CC; Gao, Y; Grupp, SA; Hirsch, B; Kahwash, S; Loh, ML; Mazor, T; Mehta, PA; Olshen, AB; Parker, JS; Patel, N; Pei, Q; Raimondi, S; Satwani, P; Skeens, M; Stieglitz, E; Wall, D	1
Choo, S; Cole, T; Mechinaud, F; Richards, S	1
Claxton, D; Miki, K; Mineishi, S; Naik, S; Rakszawski, K; Shike, H; Wagner, H	1
Alyea, EP; Antin, JH; Armand, P; Cutler, CS; Glotzbecker, BE; Gooptu, M; Ho, VT; Kim, HT; Koreth, J; Nageshwar, P; Nikiforow, S; Ritz, J; Soiffer, RJ	1
Antoniou, MN; Biswas, A; Buckley, SMK; Chan, JKY; Choolani, M; Dighe, NM; Johana, N; Mattar, CNZ; Sandikin, D; Shaw, SSW; Tan, KW; Tan, LG; Tan, YW; Waddington, SN	1
Feng, S; Li, J; Liu, R; Shi, X; Song, Z; Yue, Y	1
Calip, G; Oh, A; Patel, P; Rondelli, D; Sweiss, K	1
Chen, H; Chen, Y; Huang, XJ; Liu, KY; Qin, J; Wang, FR; Xu, LP; Yang, YL; Zhang, XH	1
Fang, X; Jiang, Y; Li, Y; Liu, X; Sui, X; Wang, X; Xu, H; Zhang, L	1
Bredius, RGM; Bresters, D; Jacobse, J; Kollen, WJW; Mensink, H; van der Stoep-Yap, MYEC	1
Fauble, V; Hogan, WJ; Jain, T; Khera, N; Kunze, KL; Leis, JF; Mesa, RA; Noel, P; Palmer, J; Partain, DK; Patnaik, MS; Roy, V; Slack, JL; Sproat, LZ; Temkit, M	1
Abraham, A; Ahn, KW; Artz, A; Boelens, JJ; Dvorak, C; Fei, M; Frangoul, H; Freytes, C; Gale, RP; Harris, AC; Hong, S; Lazarus, HM; Levine, JE; Loren, A; Mineishi, S; Nishihori, T; O'Brien, T; Pasquini, MC; Williams, K	1
Hamilton, BK	1
Deotare, U; Khalil, MMI; Kim, DD; Lipton, JH; Messner, HA; Michelis, FV; Thyagu, S; Viswabandya, A	1
Chen, X; Huang, Y; Huang, Z; Lan, H; Ma, X; Meng, F; Sun, Q; Wu, B; Wu, S; Xu, J; Yao, Q; Zhu, Z	1
Blaise, D; Brecht, A; Cahn, JY; Heinicke, T; Hicheri, Y; Huynh, A; Labopin, M; Ledoux, MP; Milpied, N; Mohty, M; Mufti, GJ; Nagler, A; Polge, E; Savani, BN; Scheid, C; Schmid, C; Socié, G	1
Aljurf, M; Arcese, W; Beohou, E; Bonifazi, F; Bruno, B; Labopin, M; Lanza, F; Mohty, M; Nagler, A; Passweg, J; Pioltelli, P; Santarone, S; Saraceni, F; Savani, BN; Sociè, G; Stepensky, P; Yakoub-Agha, I	1
Ashkenazi, M; Avni, B; Grisariu, S; Or, R; Shapira, MY; Sheth, V; Stepensky, P	1
Blaise, D; Decroocq, J; Devillier, R; Fan, X; Fürst, S; Hu, J; Tian, L; Vey, N; Wan, M; Wang, L; Wang, LN	1
Bittenbring, J; Brecht, A; Canaani, J; Ganser, A; Labopin, M; Labussière-Wallet, H; Mayer, J; Mohty, M; Nagler, A; Savani, B; Sheth, V; Shouval, R; Volin, L	1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yahng, SA; Yoon, JH	1
Abou Mourad, Y; Abuhaleeqa, M; Daly, A; Nitta, J; Paulson, K; Seftel, MD; Speziali, C	1
Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J	1
Chen, J; Chen, L; Cheng, H; Gao, L; Hu, XX; Li, HM; Luo, YR; Ni, X; Song, XM; Tang, GS; Wang, JM; Wang, ZW; Xia, XX; Yang, D; Yang, JM; Zhang, WP; Zhou, H	1
Kanda, Y	1
Ahmed, S; Al-Atrash, G; Alousi, AM; Anderlini, P; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, SO; Hosing, CM; Im, JS; Jones, R; Kawedia, J; Kebriaei, P; Khouri, I; Marin, D; Mehta, RS; Nieto, Y; Olson, A; Oran, B; Parmar, S; Popat, UR; Qazilbash, MH; Rezvani, K; Shah, N; Shpall, EJ; Srour, SA; Valdez, BC	1
Alahdab, F; Almader-Douglas, D; Firwana, B; Jain, T; Palmer, J; Sonbol, MB	1
Alatrash, G; Andersson, BS; Champlin, RE; Chen, J; Crain, AK; Di Stasi, A; Jones, RB; Kidwell, KM; Popat, U; Shpall, EJ; Thall, PF; Zope, M	1
Alessandrino, EP; Bacigalupo, A; Bonifazi, F; Bosi, A; Bregante, S; Bruno, B; Carella, AM; Fanin, R; Finazzi, MC; Mammoliti, S; Masciulli, A; Messina, G; Milone, G; Narni, F; Patriarca, F; Pavoni, C; Rambaldi, A; Russo, D	1
Calip, GS; Oh, AL; Patel, PR; Rondelli, D; Sweiss, K	1
Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A	1
Ahmed, S; Al-Atrash, G; Alousi, AM; Anderlini, P; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, SO; Hosing, CM; Im, JS; Kebriaei, P; Khouri, I; Marin, D; Mehta, RS; Molldrem, JJ; Nieto, Y; Olson, A; Oran, B; Popat, UR; Qazilbash, MH; Rezvani, K; Shpall, EJ; Srour, SA	1
Chen, Y; Feng, J; Lin, F; Lu, N; Ma, Y; Shi, Y; Sun, L; Tang, L; Wang, N; Xing, C; Yu, K	1
Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J	1
Baggerly, KA; Benton, CB; Champlin, R; Chen, J; Konoplev, S; Konopleva, M; Liu, W; Lu, H; Shpall, E; Wang, RY; Zeng, Z	1
Blaise, D; Bramanti, S; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Devillier, R; Faucher, C; Fürst, S; Granata, A; Harbi, S; Hospital, MA; Legrand, F; Lemarie, C; Lining, W; Maisano, V; Mokart, D; Pagliardini, T; Porta, MD; Rey, J; Saillard, C; Vey, N; Weiller, PJ	1
Imanaga, H; Ohno, Y; Ohta, T; Oku, S; Sugio, Y	1
Czyż, A; Danylesko, I; Fein, JA; Nagler, A; Shem Tov, N; Shimoni, A; Shouval, R; Sobas, M; Vega, Y; Yerushalmi, R	1
Behre, G; Döhring, C; Franke, GN; Grimm, J; Hille, A; Jentzsch, M; Linke, R; Niederwieser, D; Pönisch, W; Schwind, S; Vucinic, V	1
Shimoni, A	1
Fujita, N; Fukano, R; Fukuda, T; Hashii, Y; Inagaki, J; Inoue, M; Kato, K; Kobayashi, R; Maseki, N; Mitsui, T; Mori, T; Okada, K; Sato, A; Shimoyama, T; Shindo, M; Suzuki, R; Suzumiya, J; Tabuchi, K	1
Bolwell, B; Gerds, AT; Hamilton, BK; Hanna, R; Kalaycio, M; Majhail, NS; Patel, SS; Pohlman, B; Rybicki, L; Sobecks, R	1
Blaise, D; Choi, G; Cornelissen, J; Heinicke, T; Kuball, J; Labopin, M; Mohty, M; Nagler, A; Niederwieser, D; Paul, F; Platzbecker, U; Polge, E; Potter, V; Savani, BN; Schaap, N; Sengelov, H; van Gorkom, G	1
Battiwalla, M; Brazauskas, R; Buchbinder, D; Cahoon, EK; Curtis, RE; Engels, EA; Flowers, ME; Herr, MM; Morton, LM; Shaw, BE; Tecca, HR; Tucker, MA	1
Gennery, AR; Hoenig, M; Lum, SH; Slatter, MA	1
Alousi, A; Bashir, Q; Champlin, RE; Chen, J; Ciurea, SO; Daver, N; Hosing, C; Kongtim, P; Konopleva, M; Mehta, R; Olson, A; Oran, B; Popat, U; Rondon, G; Srour, S; Varma, A	1
Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I	1
Briones, J; Brunet, S; Caballero, A; Esquirol, A; Garcia-Cadenas, I; Garrido, A; Granell, M; Martino, R; Moreno, C; Novelli, S; Querol, S; Saavedra, S; Sierra, J	1
Angelucci, E; Bacigalupo, A; Bregante, S; Bruno, B; Chiusolo, P; Grazia, CD; Grisariu, S; Iori, AP; Mordini, N; Olivieri, A; Patriarca, F; Raiola, AM; Rambaldi, A; Sica, S; Sora, F; Terruzzi, E	1
Chhabra, S; D'Souza, A; Dhakal, B; Drobyski, WR; Fenske, TS; George, G; Hamadani, M; Hari, PN; Jerkins, JH; Michaelis, LC; Narra, RK; Pasquini, MC; Rizzo, RD; Saber, W; Shah, NN; Shaw, BE; Szabo, A; Wu, R	1
Bąbol-Pokora, K; Dąbrowska-Leonik, N; Frączkiewicz, J; Gul, K; Janeczko-Czarnecka, M; Kałwak, K; Martuszewski, A; Mielcarek-Siedziuk, M; Młynarski, W; Nowak, M; Paluszkiewicz, P; Salamonowicz-Bodzioch, M; Sierżęga-Staykov, K; Ussowicz, M; Wawrzyniak-Dzierżek, E; Wolska-Kuśnierz, B	1
Dreger, P; Hegenbart, U; Herfarth, K; Luft, T; Müller-Tidow, C; Radujkovic, A	1
Al-Chami, F; Angelucci, E; Bazarbachi, A; Bonifazi, F; Bruno, B; Carella, AM; Castagna, L; El-Cheikh, J; Iori, AP; La Nasa, G; Labopin, M; Mohty, M; Nagler, A; Santarone, S; Savani, B	1
Andersen, NS; Friis, LS; Grønbæk, K; Hansen, JW; Kornblit, B; Petersen, SL; Schjødt, I; Sengeløv, H; Wedge, E	1
Akasaka, T; Atsuta, Y; Eto, T; Fukuda, T; Hidaka, M; Kanda, J; Kondo, T; Miyakoshi, S; Ota, S; Shiratori, S; Takami, A; Uchida, N; Yamashita, T; Yano, S	1
Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L	1
Choi, Y; Do, YR; Jung, SH; Kim, DS; Koh, Y; Lee, JH; Lee, S; Lee, SS; Lee, WS; Moon, JH; Mun, YC; Park, HS; Park, Y; Yang, DH; Yhim, HY; Yi, JH	1
Baron, F; Hsu, J; Van Besien, K	1
Ahmed, S; Ahn, KW; Aljurf, M; Bacher, VU; Bredeson, C; Epperla, N; Farhadfar, N; Freytes, CO; Ganguly, S; Ghosh, N; Hamadani, M; Haverkos, B; Inwards, D; Kamble, RT; Khanal, M; Kharfan-Dabaja, MA; Lazarus, HM; Lekakis, L; Litovich, C; Murthy, HS; Nishihori, T; Ramakrishnan, P; Rizzieri, DA; Sureda, A; Yared, JA	1
Ussowicz, M	1
Daly, A; Dharmani-Khan, P; Duggan, PR; Jamani, K; Jimenez-Zepeda, V; Kalra, A; Khan, FM; Ousia, S; Prokopishyn, N; Russell, JA; Storek, J; Williamson, TS	1
Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G	1
Akashi, K; Eto, T; Fujishima, N; Harada, M; Hidaka, M; Kishimoto, J; Maeda, Y; Matsumoto, K; Miyamoto, T; Mori, SI; Morita, K; Murayama, T; Sakura, T; Taniguchi, S; Teshima, T; Uchida, N; Yamashita, T; Yoshimoto, G	1
Callander, N; D'Angelo, CR; Hall, A; Hematti, P; Juckett, M; Kenkre, VP; Kim, K; Longo, W; Mattison, R; Woo, KM	1
Hino, Y; Kato, J; Kikuchi, T; Koda, Y; Matsumoto, K; Mishina, T; Mori, T; Morita, K; Nagao, Y; Ohwada, C; Okamoto, S; Onizuka, M; Onoda, M; Sakaida, E; Shimizu, H; Shono, K; Takeda, Y; Yokota, A; Yokoyama, H	1
Beelen, DW; Blaise, D; Bornhäuser, M; Byrne, JL; Fegueux, N; Giebel, S; Karadogan, I; Labopin, M; Mohty, M; Nagler, A; Rovira, M; Savani, BN; Sobczyk-Kruszelnicka, M; Spyridonidis, A; Stelljes, M	1
Chu, X; Fang, X; Geng, L; Liu, H; Qiang, P; Song, K; Sun, G; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, X; Zhu, X	1
Banet, A; Battipaglia, G; Belhocine, R; Bianchessi, A; Bonnin, A; Boussaroque, A; Brissot, E; Duléry, R; Favale, F; Hirsch, P; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Memoli, M; Mohty, M; Paviglianiti, A; Sestili, S; Van de Wyngaert, Z; Vekhoff, A	1
Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I	1
Arabi, A; Bazarbachi, A; Bekadja, MA; Bouhass, R; Brahimi, M; Osmani, S; Serradj, F; Yafour, N	1
Angelucci, E; Beauvais, D; Beelen, D; Bornhäuser, M; Castagna, L; Chevallier, P; Czerw, T; de Wreede, L; Finke, J; Hayden, P; Helbig, G; Hernández-Boluda, JC; Karakasis, D; Kröger, N; Maertens, J; Mauff, K; McLornan, D; Mear, JB; Mohty, M; Passweg, J; Polverelli, N; Reményi, P; Rifòn, J; Robin, M; Rubio, MT; Russo, D; Sirait, T; Vrhovac, R; Yakoub-Agha, I	1
Bansal, M; Bhargava, R; Chakraborty, S; Dua, V; Hamal, S; Sachdev, M	1
Brammer, JE; Choe, H; Dickerson, T; Elder, P; Jaglowski, S; Larkin, K; Mims, A; Penza, S; Puto, M; Rasor, B; Roddy, JVF; Saad, A; Vasu, S; Wall, SA; William, B; Zhao, Q	1
Kapoor, R; Rastogi, N; Yadav, SP	1
Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A	1
Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K	1
Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I	1
Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M	1
Ayash, L; Deol, A; Kim, S; Modi, D; Ratanatharathorn, V; Singh, V; Uberti, JP	1
Edahiro, T; Fujii, T; Fujino, K; Fukushima, N; Hirata, Y; Ichinohe, T; Kawase, T; Mino, T; Miyama, T; Morioka, T; Nagoshi, H; Nishizawa, M; Noma, M; Toishigawa, K; Yoshida, T	1
Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S	1
Ashida, T; Atsuta, Y; Fukuda, T; Hara, M; Ichinohe, T; Ikeda, T; Ishikawa, T; Kawakita, T; Maruyama, Y; Morishige, S; Shimomura, Y; Takada, S; Takanashi, M; Uchida, N; Wake, A; Yamamoto, H	1
Cuesta, M; Esquirol, A; Ferrà, C; Garcia-Cadenas, I; Herruzo, B; Martino, R; Pascual, MJ; Pérez, A; Sierra, J; Torio, A; Torrent, A	1
Chaudhury, S; Duerst, RE; Jacobsohn, D; Kletzel, M; Kwon, S; Rossoff, J; Schneiderman, J; Tse, WT	1
Isobe, M; Konuma, T; Monna-Oiwa, M; Okabe, M; Takahashi, S; Tojo, A	1
Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S	1
Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S	1
Atsuta, Y; Eto, T; Fukuda, T; Hara, M; Hirabayashi, S; Ichinohe, T; Kanda, Y; Kawakita, T; Kimura, T; Kondo, T; Maruyama, Y; Mizuno, S; Mukae, J; Nakano, N; Ota, S; Ozawa, Y; Shimomura, Y; Tanaka, M; Uchida, N; Yanada, M	1
Araqi Houssaini, L; Chiheb, S; Hali, F; Marnissi, F; Quessar, A	1
Agrawal, V; Ahn, KW; Aljurf, M; Bacher, U; Bashey, A; Beitinjaneh, A; Bredeson, C; Cerny, J; Chhabra, S; Copelan, E; Diaz, MA; Farhadfar, N; Farhan, S; Fretham, C; Gale, RP; Ganguly, S; Grunwald, MR; Hale, GA; Hashmi, S; Hildebrandt, GC; Jain, T; Kalaycio, M; Kharfan-Dabaja, MA; Lazarus, HM; Liesveld, JL; Litzow, M; Majhail, NS; Marks, DI; Murthy, HS; Nakamura, R; Nathan, S; Nishihori, T; Olsson, RF; Oran, B; Pawarode, A; Popat, U; Reshef, R; Rizzieri, D; Saber, W; Sabloff, M; Savani, BN; Scott, BL; Seo, S; Szer, J; van der Poel, M; Verdonck, LF; Weisdorf, D; Wirk, B; Yared, JA; Yves-Cahn, J	1
Ansari, M; Ben Hassine, K; Bittencourt, H; Bredius, RGM; Daali, Y; Kassir, N; Krajinovic, M; Lewis, V; Nath, CE; Nava, T; Shaw, PJ; Théoret, Y; Uppugunduri, CRS	1
Aoki, J; Atsuta, Y; Fukuda, T; Imada, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y	1
Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I	1
Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM	1
Adachi, H; Atsuta, Y; Doki, N; Igarashi, A; Ikegawa, S; Inamoto, K; Kaito, S; Kishida, Y; Kobayashi, T; Konishi, T; Konuma, R; Marumo, A; Mukae, J; Nagata, A; Nagata, R; Najima, Y; Noguchi, Y; Ohashi, K; Sakamaki, H; Toya, T; Wada, A; Yamada, Y	1
Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S	1
Appelbaum, FR; Cooper, JP; Deeg, HJ; Doney, K; Flowers, MED; Gooley, T; Martin, PJ; McCune, JS; McFarland, C; O'Donnell, PV; Schoch, G; Sorror, ML; Storer, BE; Yeh, AC	1
Geng, L; Li, G; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, L; Zhang, S; Zhang, X; Zhu, X	1
Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB	1
Algeri, M; Alseraihy, A; Angelucci, E; Corbacioglu, S; Cseh, A; de la Fuente, J; Fisgin, T; Galimard, JE; Isgrò, A; Kleinschmidt, K; La La Nasa, G; Lankester, A; Locatelli, F; Lüftinger, R; Peters, C; Salzer, E; Smiers, FJ; Unal, E; Yesilipek, A; Zecca, M; Zubarovskaya, N	1
Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A	1
Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B	1
Atsuta, Y; Fukuda, T; Imada, K; Ishiyama, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kimura, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y	1
Bassermann, F; Braitsch, K; Götze, KS; Herhaus, P; Hubbuch, M; Keller, U; Koch, K; Menzel, H; Schwarz, A; Verbeek, M	1
Bazarbachi, A; Bethge, W; Blau, IW; Bondarenko, S; Brecht, A; Brissot, E; Bulabois, CE; Eder, M; Einsele, H; Forcade, E; Giebel, S; Huynh, A; Labopin, M; Mohty, M; Nagler, A; Rodríguez-Arbolí, E; Savani, B; Schmid, C; Spyridonidis, A; Stölzel, F; Tischer, J; Verbeek, M	1
Arpinati, M; Baronciani, D; Bernasconi, P; Bonifazi, F; Brunello, L; Bruno, B; Busca, A; Carella, AM; Carluccio, P; Casini, M; Chiusolo, P; Ciceri, F; Cilloni, D; Cupri, A; Di Grazia, C; Gheorghiu, A; Giglio, F; Girmenia, C; Grassi, A; Grillo, G; Iori, AP; Luppi, M; Martino, M; Masciulli, A; Musso, M; Nozzoli, C; Oldani, E; Onida, F; Palazzo, G; Parma, M; Patriarca, F; Pavoni, C; Peccatori, J; Picardi, A; Proia, A; Rambaldi, A; Sacchi, N; Santarone, S; Sorasio, R; Tringali, S; Vacca, A; Vallisa, D	1
Ali, N; Bal, SK; Boughan, KM; Caimi, PF; Cooper, BW; de Lima, M; de Rezende, ACP; Gallogly, M; Hamerschlak, N; Kerbauy, L; Kerbauy, MN; Latif, BM; Malek, E; Mansur, D; Metheny, L; Otegbeye, F; Pereira, G; Ribeiro, AF; Sakuraba, R; Sanchez, G; Sekaly, RP; Sharma, AA; Tomlinson, BK; Weltman, E	1
Crodel, CC; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Linke, P; Miethke, J; Schnetzke, U; Scholl, S	1
Abraham, A; Balasubramanian, P; Devasia, AJ; Fouzia, NA; George, B; Kavitha, ML; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; Pai, AA; Selvarajan, S; Sindhuvi, E; Srivastava, A	1
Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC	1
Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC	1
Babushok, DV; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Loren, AW; Luger, SM; Maity, A; Martin, ME; Plastaras, JP; Porter, DL	1
Brissot, E; Clement, L; Dalle, JH; Gandemer, V; Grain, A; Jubert, C; Labopin, M; Michel, G; Mohty, M; Paillard, C; Plantaz, D; Pochon, C; Rialland, F; Rohrlich, PS; Sirvent, A	1
Cioccio, J; Claxton, DF; Ehmann, WC; Minagawa, K; Mineishi, S; Naik, S; Nickolich, M; Pizzola, CJ; Rakszawski, KL; Rybka, WB; Shike, H; Silar, B; Wirk, B; Zheng, H; Zhou, S	1
Balsat, M; Barraco, F; Ducastelle-Leprêtre, S; Fossard, G; Ghesquières, H; Gilis, L; Hayette, S; Heiblig, M; Huet, S; Labussière-Wallet, H; Larcher, MV; Loron, S; Meur, GL; Michallet, M; Plesa, A; Renault, M; Sujobert, P; Thérèse, RM; Thomas, X; Tigaud, I	1
Fu, Y; Gui, R; Guo, S; Li, Z; Song, Y; Wang, X; Zhan, X; Zhang, B; Zhang, W; Zhang, Y; Zhou, J; Zu, Y	1
Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z	1
Baek, S; Bong, CE; Choi, EJ; Choi, Y; Jeon, M; Kang, H; Kang, YA; Kim, SM; Lee, JH; Lee, KH; Lee, YS; Park, HS; Woo, JM	1
Davini, M; de la Maza, M; Hanmod, S; Katsanis, E; Pariury, H; Proytcheva, M; Sapp, LN; Staples, K; Truscott, L	1
Gale, RP; Halahleh, KA; Ma'koseh, M; Muradi, I; Rimawi, DH; Sultan, I	1
Arat, M; Berceanu, A; Giebel, S; Hamladji, RM; Kröger, N; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Potter, V; Rambaldi, A; Sanz, J; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R; Yakoub-Agha, I	1
Arat, M; Bourhis, JH; Cornelissen, JJ; Giebel, S; Grillo, G; Hilgendorf, I; Kröger, N; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Poiré, X; Salmenniemi, U; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R	1
Ara, T; Ashida, T; Atsuta, Y; Fukuda, T; Kamijo, K; Kanaya, M; Kim, SW; Kondo, E; Kuriyama, T; Kusumoto, S; Maseki, N; Matsuoka, KI; Mizuno, I; Mizuno, S; Nakazawa, H; Onizuka, M; Shimomura, Y; Shinohara, A; Usui, Y; Yamaguchi, M	1
Arai, Y; Atsuta, Y; Doki, N; Eto, T; Fukuda, T; Harada, K; Itoh, M; Katsuoka, Y; Kawakita, T; Kondo, T; Maruyama, Y; Matsue, K; Miyakoshi, S; Mizuno, S; Nagafuji, K; Nishiwaki, K; Shibata, S; Takada, S; Tanaka, J; Uchida, N; Yanada, M	1
Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M	1
Cascio, E; Castillo, P; Farhadfar, N; Fort, J; Fraser, A; Horn, B; Lamba, J; Moore-Higgs, G; Slayton, W	1
Fan, Z; Guo, Z; Huang, F; Jin, H; Liang, X; Lin, R; Ling, Y; Liu, C; Liu, H; Liu, Q; Liu, X; Ou, R; Qu, H; Sun, J; Wu, M; Xu, N; Xu, X; Xuan, L; Yu, S; Zhai, X; Zhang, H; Zhang, Y; Zhao, Y	1
Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ	1
Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F	1
Alshehri, H; Anteh, S; Avenoso, D; Bourlon, C; Bouziana, S; Dazzi, F; de Farias, M; Dragoi, OD; Gameil, A; Hannah, G; Kenyon, M; Krishnamurthy, P; Kulasekararaj, A; Leung, YT; Mehra, V; Pagliuca, A; Potter, V; Serpenti, F; Shah, MN; Slonim, LB; Wood, H	1
Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA	1
Carlow, DC; Hutcherson, SM; Schofield, RC	1

Reviews

16 review(s) available for fludarabine and busulfan

Article	Year
[Mantle cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2001, Volume: 42, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Rituximab; Vidarabine	2001
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation. The Journal of rheumatology. Supplement, 2001, Volume: 64 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine	2001
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood, 2002, Dec-15, Volume: 100, Issue:13 Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Bone Marrow; Busulfan; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Europe; Female; Genetic Heterogeneity; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Infections; Inflammation; Male; Melphalan; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2002
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia, 2003, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2003
[Mini-transplantation from HLA-mismatched donors]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9 Topics: Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2003
[Mini-transplantation from cord blood]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9 Topics: Busulfan; Cyclophosphamide; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2003
[Reduced-intensity stem cell transplantation (RIST) for lymphoproliferative diseases]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9 Topics: Busulfan; Cause of Death; Clinical Trials as Topic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Transplantation Conditioning; Vidarabine	2003
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environmental and molecular mutagenesis, 2010, Volume: 51, Issue:6 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Clofarabine; Cross-Linking Reagents; Hematologic Neoplasms; Humans; Preoperative Care; Stem Cell Transplantation; Vidarabine	2010
Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Liver; Myeloablative Agonists; Ovarian Neoplasms; Vidarabine; Whole-Body Irradiation	2013
Do different conditioning regimens really make a difference? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunotherapy; Medical Oncology; Middle Aged; Neoplasms; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2012
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4 Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Methotrexate; Mouth Mucosa; Myeloablative Agonists; Severity of Illness Index; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2016
Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone marrow transplantation, 2016, Volume: 51, Issue:2 Topics: Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Randomized Controlled Trials as Topic; Survival Rate; Transplantation Conditioning; Vidarabine	2016
[Treatment of Gaucher disease with allogeneic hematopoietic stem cell transplantation: report of three cases and review of literatures]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2015, Volume: 53, Issue:11 Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Gaucher Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mycophenolic Acid; Retrospective Studies; Transplantation Conditioning; Vidarabine	2015
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T Bulletin du cancer, 2017, Volume: 104, Issue:12S Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2017
Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:4 Topics: Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2019
Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency. Current allergy and asthma reports, 2019, 11-18, Volume: 19, Issue:11 Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Primary Immunodeficiency Diseases; Transplantation Conditioning; Vidarabine	2019

Trials

155 trial(s) available for fludarabine and busulfan

Article	Year
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8 Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasms; Pneumonia; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine	2001
Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation. Haematologica, 2001, Volume: 86, Issue:9 Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Methylprednisolone; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. Haematologica, 2001, Volume: 86, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Lineage; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloid Cells; Prospective Studies; Transplantation Chimera; Vidarabine	2001
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood, 2001, Dec-15, Volume: 98, Issue:13 Topics: Adult; Aged; Busulfan; Cyclophosphamide; Erythrocyte Transfusion; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Nuclear Family; Platelet Transfusion; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2001
The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone marrow transplantation, 2001, Volume: 28, Issue:8 Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Gastric Mucosa; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Middle Aged; Permeability; Prospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2001
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood, 2002, Sep-15, Volume: 100, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Vidarabine	2002
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2002, Volume: 8, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2002
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:3 Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Mycophenolic Acid; Radiotherapy, Adjuvant; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2003
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood, 2003, Aug-01, Volume: 102, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Follow-Up Studies; Graft Survival; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2003
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Annals of hematology, 2003, Volume: 82, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine	2003
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood, 2003, Sep-01, Volume: 102, Issue:5 Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine	2003
Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria. European journal of haematology, 2003, Volume: 71, Issue:2 Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2003
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood, 2004, Jan-15, Volume: 103, Issue:2 Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. Bone marrow transplantation, 2003, Volume: 32, Issue:6 Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Patient Selection; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2003
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Bone marrow transplantation, 2004, Volume: 33, Issue:9 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood, 2004, Sep-15, Volume: 104, Issue:6 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Annals of hematology, 2004, Volume: 83 Suppl 1 Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2004
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone marrow transplantation, 2004, Volume: 34, Issue:1 Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphocyte Transfusion; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler). Bone marrow transplantation, 2005, Volume: 35, Issue:3 Topics: Antigens, CD34; Antilymphocyte Serum; Busulfan; Child, Preschool; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Infant; Lymphocyte Transfusion; Mucopolysaccharidosis I; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2005
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2 Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Gemtuzumab; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunotherapy; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2005
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone marrow transplantation, 2006, Volume: 37, Issue:3 Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survival; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infusions, Intravenous; Living Donors; Male; Myeloablative Agonists; Prospective Studies; Rabbits; Transplantation Conditioning; Transplantation, Autologous; Vidarabine	2006
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone marrow transplantation, 2006, Volume: 37, Issue:4 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2006
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. British journal of haematology, 2006, Volume: 135, Issue:2 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Epidemiologic Methods; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine	2006
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone marrow transplantation, 2006, Volume: 38, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutropenia; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2006
Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Annals of hematology, 2007, Volume: 86, Issue:1 Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Middle Aged; Myeloablative Agonists; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2007
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10 Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; Cytokines; Disease-Free Survival; Family; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2006
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone marrow transplantation, 2007, Volume: 39, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Interactions; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome. Bone marrow transplantation, 2007, Volume: 39, Issue:3 Topics: Abnormalities, Multiple; Adolescent; Bone Marrow Diseases; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Pilot Projects; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2007
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Bone marrow transplantation, 2007, Volume: 39, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2007
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:3 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Matched-Pair Analysis; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2007
Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. Journal of Korean medical science, 2007, Volume: 22, Issue:2 Topics: Adolescent; Adult; Aged; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; International Cooperation; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2007
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mexico; Middle Aged; Recurrence; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine	2007
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome. International journal of hematology, 2007, Volume: 85, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. American journal of hematology, 2007, Volume: 82, Issue:10 Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Experimental hematology, 2007, Volume: 35, Issue:11 Topics: Adult; Bone Marrow Examination; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Primary Myelofibrosis; Remission Induction; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2007
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Monitoring; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2008
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Bone marrow transplantation, 2008, Volume: 41, Issue:11 Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:5 Topics: Adult; Busulfan; Cell Count; Cord Blood Stem Cell Transplantation; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myeloid; Myeloablative Agonists; Transplantation Conditioning; Treatment Failure; Vidarabine	2008
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:6 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bayes Theorem; Busulfan; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2008
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. British journal of haematology, 2008, Volume: 142, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2008
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. American journal of hematology, 2008, Volume: 83, Issue:9 Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Comorbidity; Digestive System Diseases; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Reoperation; Risk; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:8 Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Middle Aged; Myeloablative Agonists; Risk Assessment; Siblings; Survival Analysis; Survival Rate; Vidarabine	2008
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Premedication; Sirolimus; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. British journal of haematology, 2008, Volume: 143, Issue:4 Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2008
Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Family; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Middle Aged; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2009, Dec-17, Volume: 114, Issue:26 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2009
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11 Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infection Control; Infections; Male; Medical Audit; Methotrexate; Middle Aged; Myeloablative Agonists; Patient Isolation; Postoperative Complications; Rabbits; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2009
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood, 2010, Feb-04, Volume: 115, Issue:5 Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult	2010
Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood, 2010, Jul-29, Volume: 116, Issue:4 Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Survival; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2010
Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:1 Topics: Adult; Aged; Busulfan; Dose-Response Relationship, Drug; Drug Interactions; Female; Glutathione; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Pharmacokinetics; Precision Medicine; Reproducibility of Results; Vidarabine; Young Adult	2011
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997), 2010, Volume: 33, Issue:7 Topics: Aged; Busulfan; Cancer Vaccines; CD8 Antigens; Cell Proliferation; Cyclophosphamide; Cytokines; Female; Freund's Adjuvant; Humans; Immunotherapy, Adoptive; Lymphocyte Depletion; Male; MART-1 Antigen; Melanoma; Middle Aged; Peptide Fragments; Skin Neoplasms; T-Lymphocytes; Vidarabine	2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2011
Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. International journal of hematology, 2010, Volume: 92, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2010
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone marrow transplantation, 2011, Volume: 46, Issue:6 Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2011
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leukemia & lymphoma, 2010, Volume: 51, Issue:12 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2010
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6 Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busulfan; Cell Line, Tumor; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Rabbits; Remission Induction; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2011
Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:8 Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Cyclophosphamide; Drug Administration Schedule; Female; Glutathione Transferase; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Isoenzymes; Male; Middle Aged; Polymorphism, Genetic; Transplantation Conditioning; Vidarabine; Young Adult	2011
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone marrow transplantation, 2011, Volume: 46, Issue:12 Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2011
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:10 Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2011
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2011
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors. American journal of hematology, 2011, Volume: 86, Issue:5 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Medical Records; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2011
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica, 2011, Volume: 96, Issue:9 Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2011
The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study. Hematological oncology, 2012, Volume: 30, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Double-Blind Method; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucositis; Transplantation Conditioning; Vidarabine; Zinc Sulfate	2012
Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2012
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine	2011
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:3 Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine	2012
Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Models, Statistical; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Treatment Outcome; Vidarabine	2012
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone marrow transplantation, 2012, Volume: 47, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2012
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Administration Schedule; Drug Dosage Calculations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2012
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone marrow transplantation, 2012, Volume: 47, Issue:10 Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Myeloablative Agonists; Neoplasm Staging; Recovery of Function; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine	2012
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone marrow transplantation, 2012, Volume: 47, Issue:10 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2012
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:11 Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Busulfan; Child; Child, Preschool; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infant; Myeloablative Agonists; Neutrophils; Prospective Studies; Secondary Prevention; Severity of Illness Index; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2012
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood, 2012, Jul-12, Volume: 120, Issue:2 Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2012
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2013
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6 Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Gastroenteritis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2013
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3 Topics: Administration, Oral; Aged; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2013
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicen Journal of hematology & oncology, 2013, Feb-08, Volume: 6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2013
Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Pediatric blood & cancer, 2013, Volume: 60, Issue:8 Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Infant; Male; Myeloablative Agonists; Retrospective Studies; Risk Factors; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2013
Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:8 Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Male; Risk Factors; Thalassemia; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2013
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7 Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2013
Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. Journal of clinical pharmacology, 2013, Volume: 53, Issue:11 Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Cyclophosphamide; Drug Interactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Young Adult	2013
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet (London, England), 2014, Feb-01, Volume: 383, Issue:9915 Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Graft Survival; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2014
Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study. International journal of hematology, 2013, Volume: 98, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Child; Cyclophosphamide; Drug Substitution; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Pneumonia; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2013
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:5 Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vomiting; Young Adult	2014
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2014
Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Disease Progression; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2014
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. International journal of radiation oncology, biology, physics, 2014, May-01, Volume: 89, Issue:1 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult	2014
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone marrow transplantation, 2014, Volume: 49, Issue:7 Topics: Adolescent; Adult; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Prospective Studies; Siblings; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult	2014
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia, 2015, Volume: 29, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2015
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Pilot Projects; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2014
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12 Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Myeloablative Agonists; Prospective Studies; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine	2014
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-01, Volume: 32, Issue:31 Topics: Adult; Aged; Bayes Theorem; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine	2014
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial. Cancer, 2015, Feb-15, Volume: 121, Issue:4 Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:1 Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2015
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Agents; Busulfan; Cyclosporine; Female; Frail Elderly; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation	2015
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:5 Topics: Adolescent; Allografts; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine	2015
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study. Hematological oncology, 2016, Volume: 34, Issue:1 Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2016
Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Adolescent; Adult; Busulfan; Child; Female; Graft Survival; Graft vs Host Disease; Guanine Nucleotide Exchange Factors; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunophenotyping; Immunosuppressive Agents; Male; Methotrexate; Mutation; Myeloablative Agonists; Pilot Projects; Severe Combined Immunodeficiency; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine	2015
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:5 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine	2015
Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning. Bone marrow transplantation, 2015, Volume: 50, Issue:6 Topics: Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Middle Aged; Prospective Studies; Rabbits; Survival Rate; Transplantation Conditioning; Vidarabine	2015
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. European journal of haematology, 2016, Volume: 96, Issue:2 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine	2016
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a Medicine, 2015, Volume: 94, Issue:15 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult	2015
Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Stu Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:8 Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Male; Middle Aged; Prospective Studies; Recurrence; Steroids; Transplantation Conditioning; Vidarabine	2015
Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies. Bone marrow transplantation, 2015, Volume: 50, Issue:8 Topics: Adolescent; Adult; Allografts; Busulfan; Child; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Middle Aged; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Vidarabine	2015
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:10 Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Adhesion Molecules; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Radioimmunotherapy; Radioisotopes; Rhenium; T-Lymphocytes; Transplantation Conditioning; Vidarabine	2015
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:9 Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Sirolimus; Stem Cell Transplantation; Survival Rate; Tacrolimus; Vidarabine	2015
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11 Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine	2015
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:12 Topics: Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2015
Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies. Bone marrow transplantation, 2015, Volume: 50, Issue:12 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine	2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-10, Volume: 33, Issue:35 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine	2015
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F. Bone marrow transplantation, 2016, Volume: 51, Issue:3 Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine	2016
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:3 Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine	2016
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood, 2016, Mar-17, Volume: 127, Issue:11 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Risk; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult	2016
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4 Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Drug Administration Schedule; Female; Gemtuzumab; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy; Immunotoxins; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Sialic Acid Binding Ig-like Lectin 3; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine; Young Adult	2016
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. Bone marrow transplantation, 2016, Volume: 51, Issue:7 Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mucositis; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2016
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood, 2017, 04-20, Volume: 129, Issue:16 Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Siblings; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult	2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-01, Volume: 35, Issue:19 Topics: Adult; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2017
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients. Stem cells and development, 2017, 08-01, Volume: 26, Issue:15 Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Prognosis; Quality of Life; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine; Young Adult	2017
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine	2017
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:3 Topics: Adolescent; Adult; Alemtuzumab; Allografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Infant; Male; Risk Factors; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine	2018
Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning. Hematology/oncology and stem cell therapy, 2018, Volume: 11, Issue:3 Topics: Adult; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Siblings; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Vidarabine	2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric blood & cancer, 2018, Volume: 65, Issue:7 Topics: Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Myeloablative Agonists; Prognosis; Transplantation Conditioning; Vidarabine	2018
Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen. Bone marrow transplantation, 2018, Volume: 53, Issue:9 Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Survival Rate; Vidarabine	2018
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood advances, 2018, 06-12, Volume: 2, Issue:11 Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine	2018
Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen. British journal of haematology, 2018, Volume: 182, Issue:4 Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine	2018
Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:1 Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine	2019
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study. Bone marrow transplantation, 2019, Volume: 54, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Vidarabine; Young Adult	2019
Is pharmacokinetic guidance a must in busulfan regimens? The Lancet. Haematology, 2018, Volume: 5, Issue:11 Topics: Area Under Curve; Busulfan; Cyclophosphamide; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Male; Randomized Controlled Trials as Topic; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. The Lancet. Haematology, 2018, Volume: 5, Issue:11 Topics: Adolescent; Adult; Aged; Busulfan; Child; Comorbidity; Dose-Response Relationship, Drug; Drug Interactions; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Time Factors; Treatment Outcome; Vidarabine; Young Adult	2018
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:5 Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine	2019
Renal dysfunction within 90 days of FluBu4 predicts early and late mortality. Bone marrow transplantation, 2019, Volume: 54, Issue:7 Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Retrospective Studies; Survival Rate; Vidarabine	2019
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:7 Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine	2019
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica, 2019, Volume: 104, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine	2019
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:8 Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Infant; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine	2019
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. Acta haematologica, 2019, Volume: 142, Issue:3 Topics: Adult; Allografts; Benzylamines; Busulfan; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Proteomics; Signal Transduction; Transplantation Conditioning; Vidarabine	2019
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:9 Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine	2019
Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS. International journal of hematology, 2019, Volume: 110, Issue:3 Topics: Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine	2019
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Hematology/oncology and stem cell therapy, 2020, Volume: 13, Issue:3 Topics: Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine	2020
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:5 Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine	2020
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study. Frontiers of medicine, 2021, Volume: 15, Issue:1 Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pharmaceutical Preparations; Prospective Studies; Transplantation Conditioning; Vidarabine	2021
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. Leukemia research, 2020, Volume: 96 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine	2020
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EB American journal of hematology, 2021, Volume: 96, Issue:1 Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Organ Size; Primary Myelofibrosis; Registries; Retrospective Studies; Spleen; Splenectomy; Survival Rate; Vidarabine	2021
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 02-01, Volume: 39, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation	2021
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7 Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult	2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood advances, 2021, 12-28, Volume: 5, Issue:24 Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Transplantation, Homologous; Vidarabine	2021
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. Bone marrow transplantation, 2022, Volume: 57, Issue:6 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Vidarabine	2022
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy, 2022, Volume: 28, Issue:7 Topics: Adolescent; Adult; Aged; Bone Marrow; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine	2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone marrow transplantation, 2022, Volume: 57, Issue:8 Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine	2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplantation and cellular therapy, 2022, Volume: 28, Issue:8 Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat	2022
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial. Bone marrow transplantation, 2022, Volume: 57, Issue:11 Topics: Adolescent; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Transplantation Conditioning; Vidarabine; Young Adult	2022
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A British journal of haematology, 2023, Volume: 200, Issue:2 Topics: Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning	2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-10, Volume: 41, Issue:29 Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Transplantation Conditioning; Vidarabine; Young Adult	2023

Other Studies

358 other study(ies) available for fludarabine and busulfan

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations. European journal of medicinal chemistry, 2010, Volume: 45, Issue:4 Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water	2010
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Bone marrow transplantation, 1999, Volume: 23, Issue:3 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine	1999
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone marrow transplantation, 2000, Volume: 25, Issue:10 Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Life Tables; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2000
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Experimental hematology, 2000, Volume: 28, Issue:7 Topics: Adult; Antineoplastic Agents; Arthritis, Psoriatic; Autoimmunity; Busulfan; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Psoriasis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine	2000
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone marrow transplantation, 2000, Volume: 26, Issue:2 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Nuclear Family; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2000
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Experimental hematology, 2001, Volume: 29, Issue:3 Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cell Count; Child; Cohort Studies; Disease-Free Survival; Female; Graft Survival; Histocompatibility; Humans; Leukemia; Life Tables; Lymphoma, Large-Cell, Anaplastic; Male; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. American journal of hematology, 2001, Volume: 66, Issue:4 Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Methotrexate; Middle Aged; Neural Tube Defects; Program Evaluation; Recurrence; Survival Analysis; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia. Bone marrow transplantation, 2001, Volume: 27, Issue:5 Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2001
Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning. Bone marrow transplantation, 2001, Volume: 28, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Family Health; Female; Graft Survival; Humans; Immunophenotyping; Infant; Lymphocyte Activation; Metabolism, Inborn Errors; Pregnancy; Purine-Nucleoside Phosphorylase; T-Lymphocytes; Transplantation Conditioning; Transplantation, Isogeneic; Vidarabine	2001
Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation. International journal of hematology, 2001, Volume: 74, Issue:1 Topics: Adenoviridae Infections; Adenoviruses, Human; Antilymphocyte Serum; Bronchoalveolar Lavage Fluid; Busulfan; Cystitis; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Methylprednisolone; Middle Aged; Pneumonia, Viral; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2001
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone marrow transplantation, 2001, Volume: 28, Issue:3 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; Cell Culture Techniques; Child; Child, Preschool; Cytotoxicity, Immunologic; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Infections; Killer Cells, Lymphokine-Activated; Lymphocyte Activation; Male; Middle Aged; Phytohemagglutinins; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2001
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone marrow transplantation, 2001, Volume: 28, Issue:7 Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell Count; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Karyotyping; Methotrexate; Middle Aged; Monosomy; Myelodysplastic Syndromes; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. British journal of haematology, 2001, Volume: 115, Issue:1 Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine	2001
Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. British journal of haematology, 2001, Volume: 115, Issue:4 Topics: Adult; Aged; Bone Marrow Cells; Busulfan; Cell Count; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2001
[Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2002, Volume: 23, Issue:4 Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Transplantation Conditioning; Transplantation Tolerance; Vidarabine	2002
Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications. Clinical and laboratory haematology, 2002, Volume: 24, Issue:5 Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Female; Fractures, Bone; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Intellectual Disability; Male; Methylprednisolone; Mycophenolic Acid; Obesity; Peripheral Blood Stem Cell Transplantation; Prednisolone; Remission Induction; Siblings; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine	2002
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 2002, Nov-01, Volume: 100, Issue:9 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2002
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood, 2003, Jan-15, Volume: 101, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Homologous; Vidarabine	2003
Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience. Bone marrow transplantation, 2002, Volume: 30, Issue:10 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2002
Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. British journal of haematology, 2002, Volume: 119, Issue:3 Topics: Adult; Busulfan; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2002
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in medicine, 2003, Mar-15, Volume: 22, Issue:5 Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine	2003
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. Annals of hematology, 2002, Volume: 81 Suppl 2 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Survival Rate; Transplantation Conditioning; Vidarabine	2002
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine	2003
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Intestines; Life Tables; Liver; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Organ Specificity; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Severity of Illness Index; Skin; Survival Analysis; Time Factors; Tissue Donors; Transplantation Conditioning; Vidarabine; Washington; Whole-Body Irradiation	2003
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. British journal of haematology, 2003, Volume: 121, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2003
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience. Hematology (Amsterdam, Netherlands), 2003, Volume: 8, Issue:3 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2003
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-15, Volume: 21, Issue:14 Topics: Adult; Aged; Busulfan; Child; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Probability; Retrospective Studies; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2003
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood, 2004, Jan-15, Volume: 103, Issue:2 Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Disease Progression; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia, 2003, Volume: 17, Issue:10 Topics: Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Transplantation Conditioning; Vidarabine	2003
Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Journal of pediatric hematology/oncology, 2003, Volume: 25, Issue:10 Topics: Bone Marrow Transplantation; Busulfan; Chediak-Higashi Syndrome; Child, Preschool; Graft vs Host Disease; Humans; Injections, Intravenous; Male; Siblings; Time Factors; Vidarabine	2003
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Annals of hematology, 2004, Volume: 83, Issue:4 Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine	2004
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis. Bone marrow transplantation, 2004, Volume: 33, Issue:5 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine	2004
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2004, Volume: 10, Issue:1 Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Child; Child, Preschool; Cladribine; Female; Fever; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Transplantation Conditioning; Vidarabine	2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood, 2004, Aug-01, Volume: 104, Issue:3 Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2004
[Reduced intensity stem cell transplantation for metastatic renal cell carcinoma]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2004, Volume: 95, Issue:3 Topics: Adult; Busulfan; Carcinoma, Renal Cell; Cyclosporine; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kidney Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Salvage Therapy; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Vidarabine	2004
Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors. Bone marrow transplantation, 2004, Volume: 34, Issue:4 Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Fanconi Anemia; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Living Donors; Male; Postoperative Complications; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2004
Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone marrow transplantation, 2004, Volume: 34, Issue:2 Topics: Aged; Busulfan; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2004
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:5 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infection Control; Infections; Leukemia, Myeloid; Male; Middle Aged; Mycophenolic Acid; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2004
Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-01, Volume: 39, Issue:7 Topics: Antilymphocyte Serum; Busulfan; Epstein-Barr Virus Infections; Guillain-Barre Syndrome; Humans; Male; Middle Aged; Samarium; Stem Cell Transplantation; Vidarabine; Virus Activation	2004
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. British journal of haematology, 2005, Volume: 128, Issue:5 Topics: Adult; Antilymphocyte Serum; Blood Transfusion, Autologous; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Middle Aged; Pilot Projects; Primary Myelofibrosis; Prospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine	2005
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Patient Selection; Postoperative Complications; Recurrence; Renal Dialysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2005
Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 2005, Volume: 35, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Pharmacokinetics; Transplantation, Homologous; Vidarabine	2005
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin. Stem cells and development, 2005, Volume: 14, Issue:2 Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine	2005
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:6 Topics: Administration, Oral; Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2005
An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Japanese journal of clinical oncology, 2005, Volume: 35, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2005
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]. Deutsche medizinische Wochenschrift (1946), 2005, Sep-23, Volume: 130, Issue:38 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Recurrence; Regression Analysis; Remission Induction; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2005
Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen. Clinical transplantation, 2005, Volume: 19, Issue:6 Topics: Adrenoleukodystrophy; Busulfan; Child; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Male; Myeloablative Agonists; Transplantation Conditioning; Vidarabine	2005
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical Protocols; Combined Modality Therapy; Comorbidity; Deferoxamine; Disease-Free Survival; Erythrocyte Transfusion; Erythropoietin; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Hemosiderosis; Humans; Hydroxyurea; Immunosuppressive Agents; Iron Chelating Agents; Life Tables; Liver Cirrhosis; Male; Phlebotomy; Postoperative Complications; Survival Analysis; Thalassemia; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2005
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. European journal of haematology, 2006, Volume: 76, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2006
Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. American journal of hematology, 2006, Volume: 81, Issue:3 Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Male; Mexico; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2006
Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:7 Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine	2006
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. British journal of haematology, 2006, Volume: 135, Issue:3 Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Middle Aged; Postoperative Complications; Primary Myelofibrosis; Spleen; Time Factors; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2006
Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone marrow transplantation, 2006, Volume: 38, Issue:7 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Czech Republic; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hospital Costs; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Philadelphia Chromosome; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2006
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10 Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Reoperation; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2006
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2006
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2006
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12 Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2006
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone marrow transplantation, 2007, Volume: 39, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome. Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3 Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Anti-Inflammatory Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisolone; Remission Induction; Sweet Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2006
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:2 Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; beta-Thalassemia; Blood Group Incompatibility; Busulfan; Child, Preschool; Cyclosporine; Epstein-Barr Virus Infections; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Plasma Exchange; Red-Cell Aplasia, Pure; Remission, Spontaneous; Retrospective Studies; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2007
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Bone marrow transplantation, 2007, Volume: 40, Issue:2 Topics: Adolescent; Adult; Busulfan; Child; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia; Male; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Annals of hematology, 2007, Volume: 86, Issue:8 Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation. International journal of hematology, 2007, Volume: 85, Issue:3 Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2007
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica, 2007, Volume: 92, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2007
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d Blood, 2007, Aug-15, Volume: 110, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prognosis; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2007
Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood, 2007, Oct-15, Volume: 110, Issue:8 Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Factor VIII; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Hemophilia A; Humans; Mice; Swine; Transgenes; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2007
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:7 Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2007
Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning. Leukemia, 2007, Volume: 21, Issue:12 Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone marrow transplantation, 2007, Volume: 40, Issue:6 Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infections; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Regurgitation of esophageal mucosa. Mayo Clinic proceedings, 2007, Volume: 82, Issue:8 Topics: Adult; Busulfan; Esophagitis; Esophagus; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucositis; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine; Vomiting	2007
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal Leukemia, 2007, Volume: 21, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2007
Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Pediatric hematology and oncology, 2007, Volume: 24, Issue:6 Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Living Donors; Lymphocyte Depletion; Male; Melphalan; Multiple Organ Failure; Postoperative Complications; Reoperation; Retrospective Studies; Spain; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome	2007
[Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies]. Terapevticheskii arkhiv, 2007, Volume: 79, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Myeloablative Agonists; Risk; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2007
Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. Bone marrow transplantation, 2007, Volume: 40, Issue:10 Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Graft vs Host Disease; Humans; Male; Middle Aged; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. International journal of hematology, 2007, Volume: 86, Issue:3 Topics: Adolescent; Adult; Age Factors; Antilymphocyte Serum; Busulfan; Child; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Sex Factors; Survival Rate; Transplantation Conditioning; Vidarabine	2007
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia & lymphoma, 2007, Volume: 48, Issue:12 Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4 Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Graft-versus-myeloma effects in reduced-intensity cord blood transplantation. International journal of hematology, 2007, Volume: 86, Issue:5 Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Remission Induction; Retrospective Studies; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. Transplant infectious disease : an official journal of the Transplantation Society, 2008, Volume: 10, Issue:4 Topics: Adolescent; Adult; Aged; Aspergillosis; Bacteremia; Busulfan; Catheterization, Central Venous; Chronic Disease; Communicable Diseases; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pneumonia, Bacterial; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2008
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Caspase 3; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Killer Cells, Natural; Leukemia; Stem Cells; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Vidarabine	2008
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Experimental hematology, 2008, Volume: 36, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; France; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Registries; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Time; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2008
A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatric transplantation, 2008, Volume: 12, Issue:8 Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Female; History, Ancient; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Pilot Projects; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor. American journal of hematology, 2008, Volume: 83, Issue:8 Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Vidarabine	2008
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Umbilical cord-blood transplantations from unrelated donors in patients with inherited metabolic diseases: Single-institute experience. Pediatric transplantation, 2008, Volume: 12, Issue:6 Topics: Administration, Oral; Busulfan; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Lysosomal Storage Diseases; Male; Methotrexate; Peroxisomal Disorders; Vidarabine	2008
Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunologic research, 2009, Volume: 44, Issue:1-3 Topics: Adolescent; Busulfan; Child; Child, Preschool; Chimerism; Cyclophosphamide; Follow-Up Studies; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Kaplan-Meier Estimate; Male; Melphalan; Postoperative Complications; Pulmonary Aspergillosis; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult	2009
Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT. Leukemia research, 2009, Volume: 33, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Fetal Blood; Humans; Male; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2009
Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:1 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cyclosporine; Female; Glomerular Filtration Rate; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Premedication; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult	2009
Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone marrow transplantation, 2009, Volume: 44, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Transplantation Conditioning; Vidarabine; Young Adult	2009
Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antigens, Viral; Bone Marrow Transplantation; Busulfan; Cytomegalovirus Infections; Disease Susceptibility; Female; Humans; Immunosuppressive Agents; Incidence; Intestinal Mucosa; Japan; Male; Middle Aged; Myeloablative Agonists; Postoperative Complications; Radiation Injuries; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult	2009
Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone marrow transplantation, 2010, Volume: 45, Issue:1 Topics: Adult; Aged; Anthracyclines; Arrhythmias, Cardiac; Busulfan; Female; Heart Diseases; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2010
Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma. Pediatric transplantation, 2010, Volume: 14, Issue:1 Topics: Adolescent; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Myeloablative Agonists; Positron-Emission Tomography; Severity of Illness Index; Time Factors; Transplantation, Homologous; Treatment Outcome; Vidarabine	2010
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting. Blood transfusion = Trasfusione del sangue, 2009, Volume: 7, Issue:2 Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Donors; Busulfan; Catheter Ablation; Cost-Benefit Analysis; Cyclophosphamide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mexico; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2009
Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT. Bone marrow transplantation, 2010, Volume: 45, Issue:1 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Clinical Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2010
Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone marrow transplantation, 2010, Volume: 45, Issue:2 Topics: Adolescent; Adult; Area Under Curve; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine	2010
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Current opinion in oncology, 2009, Volume: 21 Suppl 1 Topics: Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cohort Studies; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Rabbits; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2009
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients. Leukemia research, 2010, Volume: 34, Issue:4 Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemotherapy, Adjuvant; Dasatinib; Humans; Immunosuppressive Agents; Leukemia; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2010
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:4 Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2010
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:6 Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine	2010
Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients. American journal of hematology, 2010, Volume: 85, Issue:4 Topics: Adult; Aged; Aging; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2010
Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone marrow transplantation, 2011, Volume: 46, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Chimerism; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Myeloablative Agonists; T-Lymphocytes; Transplantation Conditioning; Transplantation, Heterologous; Vidarabine; Whole-Body Irradiation; Young Adult	2011
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20 Topics: Adolescent; Adult; Busulfan; Drug Therapy, Combination; Feasibility Studies; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2010
Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement. International journal of radiation oncology, biology, physics, 2011, May-01, Volume: 80, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Confidence Intervals; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Transplantation Conditioning; Vidarabine; Young Adult	2011
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone marrow transplantation, 2011, Volume: 46, Issue:5 Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Treatment Outcome; Vidarabine	2011
Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:5 Topics: Administration, Oral; Adult; Animals; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Female; Forced Expiratory Volume; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lung; Male; Middle Aged; Myeloablative Agonists; Pulmonary Diffusing Capacity; Rabbits; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vital Capacity	2011
Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6 Topics: Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Longitudinal Studies; Lymphocyte Count; Male; Melphalan; Multivariate Analysis; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine	2011
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Experimental hematology, 2010, Volume: 38, Issue:12 Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine	2010
Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. American journal of hematology, 2010, Volume: 85, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Survival Rate; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2010
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. Journal of hematology & oncology, 2010, Oct-06, Volume: 3 Topics: Area Under Curve; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2010
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochemical pharmacology, 2011, Jan-15, Volume: 81, Issue:2 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Clofarabine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine	2011
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG. Bone marrow transplantation, 2011, Volume: 46, Issue:8 Topics: Age Factors; Aged; Antilymphocyte Serum; Busulfan; Comorbidity; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2011
Unrelated donor transplantation for acute myelogenous leukemia in first remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Salvage Therapy; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2011
Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone marrow transplantation, 2011, Volume: 46, Issue:11 Topics: Adult; Aged; Area Under Curve; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine	2011
Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4). Bone marrow transplantation, 2011, Volume: 46, Issue:10 Topics: Adolescent; Adult; Busulfan; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2011
Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring. Leukemia & lymphoma, 2010, Volume: 51, Issue:12 Topics: Busulfan; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Maximum Tolerated Dose; Monitoring, Physiologic; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2010
Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:9 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Graft Survival; Humans; Infant; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult	2011
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. International journal of hematology, 2011, Volume: 93, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Retrospective Studies; Rituximab; Transplantation Conditioning; Vidarabine	2011
A transient IgE monoclonal protein in a child. Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 1 Topics: Adrenoleukodystrophy; Antibodies, Monoclonal; Busulfan; Child; Cyclosporine; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Immunoglobulin E; Immunosuppressive Agents; Vidarabine; Virus Activation	2011
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning. Leukemia & lymphoma, 2011, Volume: 52, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematological oncology, 2011, Volume: 29, Issue:4 Topics: Adult; Aged; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Opportunistic Infections; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2011
[Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation]. Methods and findings in experimental and clinical pharmacology, 2010, Volume: 32 Suppl A Topics: Adolescent; Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2010
Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation. International journal of hematology, 2011, Volume: 93, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chimerism; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Vidarabine; Young Adult	2011
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation. Bone marrow transplantation, 2012, Volume: 47, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2012
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:11 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2011
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. Leukemia research, 2011, Volume: 35, Issue:8 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Primary Myelofibrosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2011
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood, 2011, Sep-01, Volume: 118, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Infections; Kaplan-Meier Estimate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2011
Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Neoplasma, 2011, Volume: 58, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2011
Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin. Leukemia & lymphoma, 2012, Volume: 53, Issue:1 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult	2012
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. British journal of haematology, 2011, Volume: 155, Issue:2 Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Genetic Diseases, Inborn; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Melphalan; Myeloablative Agonists; Neoplasms; Neutrophils; Recombinant Proteins; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2011
Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. Journal of clinical immunology, 2012, Volume: 32, Issue:1 Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; CD3 Complex; Child; Down-Regulation; Female; Forkhead Transcription Factors; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hyaluronan Receptors; Immunosuppression Therapy; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Leukocytes, Mononuclear; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Myeloablative Agonists; Protein Binding; Rabbits; Radiation Tolerance; T-Lymphocytes, Regulatory; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2012
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma. Journal of pediatric surgery, 2011, Volume: 46, Issue:11 Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine	2011
Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine. European journal of haematology, 2012, Volume: 88, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Mucositis; Myeloablative Agonists; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2012
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leukemia & lymphoma, 2012, Volume: 53, Issue:8 Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Area Under Curve; Biopsy; Busulfan; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Liver; Male; Middle Aged; Stem Cell Transplantation; Time Factors; Vidarabine	2012
Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys. Molecular therapy : the journal of the American Society of Gene Therapy, 2012, Volume: 20, Issue:5 Topics: Animals; Animals, Newborn; Busulfan; Genes, Reporter; Genetic Vectors; Graft Survival; Green Fluorescent Proteins; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Immune Tolerance; Immunosuppressive Agents; Lentivirus; Macaca mulatta; Simian Immunodeficiency Virus; Transduction, Genetic; Transgenes; Transplantation Conditioning; Vidarabine	2012
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone marrow transplantation, 2012, Volume: 47, Issue:5 Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Rabbits; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine	2012
Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2011, Volume: 155, Issue:4 Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2011
Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy. The Korean journal of internal medicine, 2012, Volume: 27, Issue:1 Topics: Adolescent; Adult; Busulfan; Chi-Square Distribution; Disease-Free Survival; Drug Therapy, Combination; Feasibility Studies; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2012
Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency. Pediatric transplantation, 2013, Volume: 17, Issue:1 Topics: Adenosine Deaminase; Agammaglobulinemia; Bone Marrow Transplantation; Busulfan; Child, Preschool; Humans; Living Donors; Male; Severe Combined Immunodeficiency; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine	2013
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:12 Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Comorbidity; Disease-Free Survival; Humans; Incidence; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2012
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer, 2013, Mar-01, Volume: 119, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Drug Administration Schedule; Female; Graft vs Host Reaction; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult	2013
Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL. Bone marrow transplantation, 2013, Volume: 48, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia; Busulfan; Child, Preschool; Humans; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine	2013
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3 Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2013
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone marrow transplantation, 2013, Volume: 48, Issue:5 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Erythema; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult	2013
[A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia]. Zhonghua nei ke za zhi, 2012, Volume: 51, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult	2012
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). European journal of haematology, 2013, Volume: 90, Issue:3 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Innate; Leukemia; Lymphoma; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recovery of Function; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2013
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:4 Topics: Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Graft Rejection; Graft Survival; Humans; Infant; Male; Myeloablative Agonists; Transplantation Conditioning; Unrelated Donors; Vidarabine	2013
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine	2013
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2013
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6 Topics: Aged; Busulfan; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine	2013
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7 Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Transfusion; Male; Methotrexate; Middle Aged; Pilot Projects; Secondary Prevention; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2013
Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma. Pediatric transplantation, 2013, Volume: 17, Issue:6 Topics: Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Neutrophils; Remission Induction; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome	2013
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leukemia & lymphoma, 2014, Volume: 55, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoprevention; Chronic Disease; Disease Progression; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Recurrence; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2014
Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:9 Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation, Homologous; Vidarabine	2013
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone marrow transplantation, 2014, Volume: 49, Issue:1 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2014
Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report. Transplantation proceedings, 2013, Volume: 45, Issue:7 Topics: Acute Disease; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Crohn Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Transplantation Conditioning; Vidarabine	2013
An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution. PloS one, 2013, Volume: 8, Issue:9 Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lung Diseases; Lymphocytes; Male; Middle Aged; Mucositis; Outcome Assessment, Health Care; Proportional Hazards Models; Quality of Life; Recovery of Function; Retrospective Studies; Surveys and Questionnaires; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2013
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Leukemia research, 2013, Volume: 37, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2013
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. American journal of hematology, 2014, Volume: 89, Issue:1 Topics: Adult; Age Factors; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Middle Aged; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2014
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leukemia & lymphoma, 2014, Volume: 55, Issue:7 Topics: Adenine Nucleotides; Antineoplastic Agents, Alkylating; Apoptosis; Arabinonucleosides; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Clofarabine; DNA Damage; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Mitochondria; Nuclear Proteins; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine	2014
Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Adenoviridae Infections; Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Lung; Male; Myeloablative Agonists; Roseolovirus Infections; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2014
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2014
Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Adolescent; Adult; Aged; Busulfan; Cross Infection; Female; Graft vs Host Disease; Health Care Costs; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Patient Readmission; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2014
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Pediatric blood & cancer, 2014, Volume: 61, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2014
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience. Annals of transplantation, 2014, Jan-08, Volume: 19 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Myeloablative Agonists; Prognosis; Retrospective Studies; Risk Factors; Transplantation Conditioning; Vidarabine; Young Adult	2014
[The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies]. Zhonghua nei ke za zhi, 2013, Volume: 52, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult	2013
Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT. Bone marrow transplantation, 2014, Volume: 49, Issue:5 Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Lung Diseases; Lymphocyte Depletion; Male; Middle Aged; Myeloablative Agonists; Respiratory Function Tests; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2014
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multivariate Analysis; Oral Hygiene; Prednisone; Sirolimus; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult	2014
Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience. Leukemia research, 2014, Volume: 38, Issue:5 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2014
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. Bone marrow transplantation, 2014, Volume: 49, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2014
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:6 Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine	2015
Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2014
Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12 Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Risk Factors; Survival Rate; Thalassemia; Transplantation Conditioning; Vidarabine	2014
The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD. Bone marrow transplantation, 2014, Volume: 49, Issue:12 Topics: Adolescent; Adult; Aged; BK Virus; Busulfan; Cystitis; Cytomegalovirus Infections; Female; Graft vs Host Disease; HLA Antigens; Humans; Male; Middle Aged; Multivariate Analysis; Polyomavirus Infections; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Viremia; Young Adult	2014
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine	2014
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome. Pediatric hematology and oncology, 2014, Volume: 31, Issue:8 Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2014
[The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation]. Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:6 Topics: Anemia, Aplastic; Busulfan; Graft vs Host Disease; Hematologic Diseases; Histocompatibility; HLA Antigens; Humans; Incidence; Methotrexate; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine	2014
Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease. Pediatric blood & cancer, 2015, Volume: 62, Issue:2 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child, Preschool; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Transplantation Conditioning; Vidarabine	2015
Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning. Pediatric blood & cancer, 2015, Volume: 62, Issue:2 Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Thiotepa; Vidarabine	2015
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2014, Volume: 45, Issue:4 Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2014
A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Female; Graft Survival; Graft vs Host Disease; Haplotypes; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2015
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer, 2015, Apr-01, Volume: 121, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Young Adult	2015
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:2 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2015
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Hematological oncology, 2016, Volume: 34, Issue:3 Topics: Aged; Allografts; Busulfan; Disease-Free Survival; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine	2016
Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation. Bone marrow transplantation, 2015, Volume: 50, Issue:3 Topics: Antilymphocyte Serum; Busulfan; Child, Preschool; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2015
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan. International journal of hematology, 2015, Volume: 101, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Retreatment; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2015
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents. Pediatric blood & cancer, 2015, Volume: 62, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Japan; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2015
A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. Bone marrow transplantation, 2015, Volume: 50, Issue:4 Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Comorbidity; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Vidarabine	2015
I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases. Bone marrow transplantation, 2015, Volume: 50, Issue:4 Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Hematologic Diseases; Humans; Male; Melphalan; Middle Aged; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2015
Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP. Bone marrow transplantation, 2015, Volume: 50, Issue:4 Topics: Adolescent; Allografts; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Databases, Factual; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Quality of Health Care; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine	2015
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:2 Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult	2015
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6 Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Experimental hematology, 2015, Volume: 43, Issue:6 Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine	2015
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Mucopolysaccharidoses; Myeloablative Agonists; Neurodegenerative Diseases; Practice Guidelines as Topic; Prognosis; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine	2015
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Annals of hematology, 2015, Volume: 94, Issue:6 Topics: Adult; Aged; Busulfan; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2015
Permanent chemotherapy-induced nonscarring alopecia and premature ovarian failure. Clinical and experimental dermatology, 2015, Volume: 40, Issue:5 Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Primary Ovarian Insufficiency; Thiotepa; Vidarabine	2015
[Establishment of a graft-versus-host disease mouse model for haplo-identical bone marrow transplantation with busulfan and fludarabine conditioning regimen]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:3 Topics: Animals; Bone Marrow Transplantation; Busulfan; Disease Models, Animal; Drug Combinations; Graft vs Host Disease; Mice; Transplantation Conditioning; Vidarabine	2015
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone marrow transplantation, 2015, Volume: 50, Issue:7 Topics: Adult; Aged; Benzylamines; Busulfan; Cell Movement; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Diagnosis: Melanoderma after Hematopoietic Stem Cell Transplantation. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:4 Topics: Antilymphocyte Serum; Busulfan; Deferoxamine; Diagnosis, Differential; Ecchymosis; Humans; Infant; Iron Overload; Male; Melanosis; Peripheral Blood Stem Cell Transplantation; Severe Combined Immunodeficiency; Transfusion Reaction; Transplantation Conditioning; Vidarabine	2015
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Leukemia research, 2015, Volume: 39, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center. Transplantation proceedings, 2015, Volume: 47, Issue:4 Topics: Adult; Antilymphocyte Serum; Busulfan; Cohort Studies; Cross-Sectional Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2015, Volume: 13, Issue:5 Topics: Adult; Antigens, CD34; Antilymphocyte Serum; B-Lymphocyte Subsets; Blood Component Removal; Busulfan; Cross-Sectional Studies; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Factors; T-Lymphocyte Subsets; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Turkey; Vidarabine	2015
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:6 Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa. The Journal of pediatrics, 2015, Volume: 167, Issue:3 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Epithelial Cells; Fibroblasts; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Mutation; Myeloablative Agonists; RNA, Messenger; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11 Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:6 Topics: Adult; Aged; Allografts; Busulfan; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine	2015
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis. Bone marrow transplantation, 2015, Volume: 50, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease Progression; Female; Graft Survival; Humans; Janus Kinase 2; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Polycythemia Vera; Primary Myelofibrosis; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2015
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Female; Gene Expression; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Myeloablative Agonists; Pilot Projects; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine	2015
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. Pediatric blood & cancer, 2016, Volume: 63, Issue:1 Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Europe; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Multivariate Analysis; Retrospective Studies; Societies, Medical; Transplantation Conditioning; Treatment Outcome; Vidarabine	2016
Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies. Annals of hematology, 2016, Volume: 95, Issue:1 Topics: Adult; Aged; Bone Marrow Diseases; Busulfan; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2016
Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies. Journal of chromatographic science, 2016, Volume: 54, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Biphenyl Compounds; Busulfan; Child; Child, Preschool; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Ditiocarb; Epoxy Compounds; Female; Humans; Infant; Male; Methanol; Prodrugs; Reference Standards; Solvents; Vidarabine; Water	2016
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. The Lancet. Haematology, 2015, Volume: 2, Issue:10 Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2015
[Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:12 Topics: Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Methotrexate; Mycophenolic Acid; Retrospective Studies; Siblings; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine	2015
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel Leukemia & lymphoma, 2016, Volume: 57, Issue:10 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comorbidity; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2016
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia]. Zhonghua nei ke za zhi, 2016, Volume: 55, Issue:3 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2016
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7 Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine	2016
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? The Korean journal of internal medicine, 2016, Volume: 31, Issue:4 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Living Donors; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Recurrence; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine	2016
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study. Annals of hematology, 2016, Volume: 95, Issue:7 Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Cells; Busulfan; Cyclophosphamide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2016
Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? Bone marrow transplantation, 2016, Volume: 51, Issue:7 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2016
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2 Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Leukemia; Mycophenolic Acid; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2016
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Middle Aged; Myeloablative Agonists; Pneumonia; Prospective Studies; Seizures; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2016
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2016
Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leukemia research, 2016, Volume: 47 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Chromatin Assembly and Disassembly; Clofarabine; Depsipeptides; DNA Damage; Drug Synergism; Histone Code; Humans; Metabolic Networks and Pathways; Tumor Cells, Cultured; Vidarabine	2016
Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning. Bone marrow transplantation, 2016, Volume: 51, Issue:11 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases; Male; Myeloablative Agonists; Respiratory Function Tests; Transplantation Conditioning; Vidarabine; Young Adult	2016
A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adult; Aged; Busulfan; Female; Graft Survival; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2016
Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:13 Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2016
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, B-Cell; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2016
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2016
Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies. Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:8 Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid; Male; Melphalan; Myeloablative Agonists; Myeloproliferative Disorders; Remission Induction; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2016
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine	2016
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies]. Zhonghua yi xue za zhi, 2016, Jul-26, Volume: 96, Issue:28 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2016
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies. Oncotarget, 2016, Nov-29, Volume: 7, Issue:48 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult	2016
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:2 Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult	2017
Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia. Haematologica, 2017, Volume: 102, Issue:3 Topics: Anemia, Diamond-Blackfan; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine	2017
[Clinical Efficacy of Haploidentical Allo-HSCT of Reduced Intensity Preconditioning Combined with Induced Immune Tolerance after Transplantation for Severe Aplastic Anemia]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:6 Topics: Anemia, Aplastic; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Fathers; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Immune Tolerance; Male; Methotrexate; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine	2016
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:5 Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2017
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Journal of hematology & oncology, 2017, 01-24, Volume: 10, Issue:1 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Leukocyte Reduction Procedures; Lymphocyte Depletion; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2017
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning. Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3 Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Length of Stay; Male; Middle Aged; Myeloablative Agonists; Polyomavirus Infections; Recurrence; Risk Factors; Sex Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2017
Successful Myeloablative Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in a Young Girl With GATA2 Deficiency and Emberger Syndrome. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:3 Topics: Busulfan; Child, Preschool; Female; GATA2 Transcription Factor; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphedema; Myeloablative Agonists; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine	2017
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood. Bone marrow transplantation, 2017, Volume: 52, Issue:7 Topics: Acute Disease; Adolescent; Adult; Alopecia; Busulfan; Child; Child, Preschool; Cross-Sectional Studies; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Risk Factors; Transplantation Conditioning; Vidarabine	2017
Influences of FLU/BU and FLU/MEL on incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2017, Volume: 58, Issue:3 Topics: Adult; Aged; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2017
Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017, Jun-15, Volume: 1055-1056 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Chromatography, Liquid; Clofarabine; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Isotopes; Limit of Detection; Tandem Mass Spectrometry; Transplantation Conditioning; Vidarabine	2017
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. American journal of hematology, 2017, Volume: 92, Issue:10 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult	2017
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:12 Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Melphalan; Middle Aged; Myelodysplastic Syndromes; Rabbits; Risk Assessment; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2017
Persistence of the losing cord blood unit following double cord blood transplantation: finding the unseen. Blood, 2017, 09-21, Volume: 130, Issue:12 Topics: Adolescent; Adult; Blood Cells; Bone Marrow Cells; Busulfan; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Hematopoiesis; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult	2017
Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:4 Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Patient Selection; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2018
Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. International journal of hematology, 2017, Volume: 106, Issue:4 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cystitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Vascular Diseases; Vidarabine	2017
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:12 Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2017
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cel Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Sep-01, Volume: 28, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2017
HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:1 Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Cohort Studies; Dexamethasone; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Transplantation, Haploidentical; Transplantation, Homologous; Vidarabine; Young Adult	2018
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclophosphamide; Databases, Factual; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2018
Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:2 Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Mycophenolic Acid; Premedication; Tacrolimus; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2018
Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies. Bone marrow transplantation, 2018, Volume: 53, Issue:2 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2018
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:6 Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Infant; Italy; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2018
Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. Pediatric blood & cancer, 2018, Volume: 65, Issue:6 Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Melphalan; Myeloablative Agonists; Osteopetrosis; Prognosis; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult	2018
Single centre results of targeted busulphan, fludarabine and serotherapy conditioning in haematopoietic stem cell transplantation for haemophagocytic lymphohistiocytosis. Bone marrow transplantation, 2018, Volume: 53, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunization, Passive; Lymphohistiocytosis, Hemophagocytic; Male; Transplantation Conditioning; Vidarabine	2018
Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML. International journal of hematology, 2018, Volume: 108, Issue:3 Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Tumor Burden; Vidarabine	2018
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8 Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2018
A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model. Experimental hematology, 2018, Volume: 62 Topics: Animals; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Cell Survival; Cellular Microenvironment; Disease Models, Animal; Female; Fetal Therapies; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Hepatocytes; Lentivirus; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Transplantation Chimera; Transplantation Conditioning; Vidarabine	2018
Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis. Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:6 Topics: Allografts; Antilymphocyte Serum; Busulfan; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Male; Mucopolysaccharidoses; Survival Rate; Transplantation Conditioning; Vidarabine	2018
Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis. Bone marrow transplantation, 2018, Volume: 53, Issue:6 Topics: Adrenoleukodystrophy; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucopolysaccharidoses; Transplantation Conditioning; Transplantation, Haploidentical; Transplantation, Homologous; Vidarabine	2018
Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018, Volume: 16, Issue:6 Topics: Adolescent; Adult; Busulfan; China; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult	2018
Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation. Bone marrow transplantation, 2018, Volume: 53, Issue:10 Topics: Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Busulfan; Cyclosporine; Gastroparesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Methotrexate; Nausea; Unrelated Donors; Vidarabine; Vomiting	2018
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone marrow transplantation, 2019, Volume: 54, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2019
TBI: To Be (Irradiated) or Not To Be? That Remains the Question. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8 Topics: Busulfan; Cyclophosphamide; Vidarabine; Whole-Body Irradiation	2018
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Ontario; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2018
Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpla Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:11 Topics: Busulfan; Europe; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Vidarabine	2018
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. American journal of hematology, 2018, Volume: 93, Issue:10 Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Drug Evaluation; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Retrospective Studies; Siblings; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult	2018
Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation. Pediatric blood & cancer, 2018, Volume: 65, Issue:11 Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Retrospective Studies; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2018
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes. Bone marrow transplantation, 2019, Volume: 54, Issue:3 Topics: Adolescent; Adult; Busulfan; China; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Vidarabine; Young Adult	2019
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone marrow transplantation, 2019, Volume: 54, Issue:4 Topics: Aged; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine	2019
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Leukemia & lymphoma, 2019, Volume: 60, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2019
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. Journal of hematology & oncology, 2018, 08-30, Volume: 11, Issue:1 Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Young Adult	2018
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone marrow transplantation, 2019, Volume: 54, Issue:8 Topics: Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Journal of hematology & oncology, 2019, 04-25, Volume: 12, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult	2019
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis. Bone marrow transplantation, 2020, Volume: 55, Issue:1 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine	2020
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients. Stem cells and development, 2019, 10-15, Volume: 28, Issue:20 Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine	2019
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. American journal of hematology, 2019, Volume: 94, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2019
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity. The Lancet. Haematology, 2020, Volume: 7, Issue:1 Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine	2020
Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma. International journal of hematology, 2019, Volume: 110, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2019
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone marrow transplantation, 2020, Volume: 55, Issue:4 Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine	2020
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. Journal of the American Academy of Dermatology, 2020, Volume: 83, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Busulfan; Case-Control Studies; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Karnofsky Performance Status; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Staging; Risk Factors; Skin; Skin Neoplasms; Tissue Donors; Transplantation Conditioning; Ultraviolet Rays; Vidarabine; Whole-Body Irradiation; Young Adult	2020
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood, 2020, 02-06, Volume: 135, Issue:6 Topics: Age Factors; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2020
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation. Pediatric transplantation, 2020, Volume: 24, Issue:1 Topics: Busulfan; Child; Child, Preschool; Drug Eruptions; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine	2020
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t Annals of hematology, 2020, Volume: 99, Issue:1 Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplasms; HLA Antigens; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine	2020
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:4 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine	2020
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:5 Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Transplantation Conditioning; Vidarabine	2020
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report. Transplantation proceedings, 2020, Volume: 52, Issue:2 Topics: Antilymphocyte Serum; Busulfan; Ectodermal Dysplasia; Hematopoietic Stem Cell Transplantation; Humans; I-kappa B Kinase; Immunologic Deficiency Syndromes; Infant; Male; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2020
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience. Annals of hematology, 2020, Volume: 99, Issue:4 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms, Second Primary; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2020
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:6 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2020
Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan. Bone marrow transplantation, 2020, Volume: 55, Issue:10 Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Vidarabine	2020
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa. Transplantation, 2021, 04-01, Volume: 105, Issue:4 Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Retrospective Studies; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2021
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei medical journal, 2020, Volume: 61, Issue:6 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2020
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? Leukemia & lymphoma, 2020, Volume: 61, Issue:7 Topics: Busulfan; Humans; Leukemia, Myeloid, Acute; Melphalan; Transplantation Conditioning; Vidarabine	2020
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA oncology, 2020, 07-01, Volume: 6, Issue:7 Topics: Allografts; Busulfan; Cohort Studies; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Melphalan; Myeloablative Agonists; Recurrence; Registries; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2020
Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation. Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:6 Topics: Busulfan; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine	2020
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin. Clinical transplantation, 2020, Volume: 34, Issue:9 Topics: Aged; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myeloablative Agonists; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2020
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia & lymphoma, 2020, Volume: 61, Issue:8 Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Sirolimus; Tacrolimus; Thiotepa; Transplantation Conditioning; Vidarabine	2020
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies. International journal of hematology, 2020, Volume: 112, Issue:4 Topics: Age Factors; Aged; Busulfan; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Radiation Dosage; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2020
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. International journal of hematology, 2021, Volume: 113, Issue:1 Topics: Adult; Age Factors; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2021
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acut Bone marrow transplantation, 2021, Volume: 56, Issue:2 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2021
Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult	2020
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. Leukemia & lymphoma, 2021, Volume: 62, Issue:2 Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Thiotepa; Transplantation Conditioning; Vidarabine	2021
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. Bone marrow transplantation, 2021, Volume: 56, Issue:3 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine	2021
Improving survival rates for patients with acute myeloid leukemia: Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT. Current research in translational medicine, 2020, Volume: 68, Issue:4 Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Humans; Leukemia, Myeloid, Acute; Survival Rate; Transplantation Conditioning; Vidarabine	2020
Haploidentical Stem Cell Transplant With Post-transplant Cyclophosphamide for Chediak-Higashi Syndrome: A Very Rare Case Report. Journal of pediatric hematology/oncology, 2021, Oct-01, Volume: 43, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chediak-Higashi Syndrome; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Prognosis; Transplantation Conditioning; Vidarabine	2021
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS. Leukemia & lymphoma, 2021, Volume: 62, Issue:4 Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2021
Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning. Journal of pediatric hematology/oncology, 2021, 05-01, Volume: 43, Issue:4 Topics: Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine	2021
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone marrow transplantation, 2021, Volume: 56, Issue:7 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine	2021
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. Journal of clinical immunology, 2021, Volume: 41, Issue:5 Topics: Busulfan; Child, Preschool; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Leukocyte Count; Male; Melphalan; Primary Immunodeficiency Diseases; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine	2021
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis. Annals of hematology, 2021, Volume: 100, Issue:4 Topics: Aged; Allografts; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Progression-Free Survival; Retrospective Studies; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation	2021
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2021
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. Journal of pediatric hematology/oncology, 2021, Oct-01, Volume: 43, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2021
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. Bone marrow transplantation, 2021, Volume: 56, Issue:7 Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Propensity Score; Transplantation Conditioning; Vidarabine	2021
Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. Transplantation and cellular therapy, 2021, Volume: 27, Issue:7 Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Thiotepa; Transplantation Conditioning; Vidarabine	2021
Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatric blood & cancer, 2021, Volume: 68, Issue:8 Topics: Antilymphocyte Serum; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2021
Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults. European journal of haematology, 2021, Volume: 107, Issue:3 Topics: Adult; Blood Platelets; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Neutrophils; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine	2021
Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation. Asian Pacific journal of cancer prevention : APJCP, 2021, May-01, Volume: 22, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Iran; Male; Middle Aged; Prognosis; Quality of Life; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2021
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT. Cancer medicine, 2021, Volume: 10, Issue:13 Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2021
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone marrow transplantation, 2021, Volume: 56, Issue:9 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine	2021
[Cutaneous complications following hematopoietic stem cell transplantation]. Bulletin du cancer, 2021, Volume: 108, Issue:9 Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Disease; Dermatomycoses; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Genitalis; Humans; Induction Chemotherapy; Malassezia; Male; Melphalan; Middle Aged; Morocco; Prospective Studies; Skin Diseases; Skin Diseases, Infectious; Vidarabine; Young Adult	2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and cellular therapy, 2021, Volume: 27, Issue:11 Topics: Aged; Busulfan; Graft vs Host Disease; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Vidarabine	2021
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:9 Topics: Administration, Intravenous; Adolescent; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Glutathione Transferase; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Models, Biological; Polymorphism, Genetic; Precision Medicine; Transplantation Conditioning; Vidarabine; Young Adult	2021
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. Bone marrow transplantation, 2021, Volume: 56, Issue:12 Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Propensity Score; Retrospective Studies; Transplantation Conditioning; Vidarabine	2021
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. British journal of haematology, 2021, Volume: 195, Issue:3 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2021
Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI. International journal of hematology, 2022, Volume: 115, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2022
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:10 Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine	2022
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone marrow transplantation, 2022, Volume: 57, Issue:2 Topics: Antilymphocyte Serum; Busulfan; Chimerism; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine	2022
Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning. Pediatric transplantation, 2022, Volume: 26, Issue:2 Topics: Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Retrospective Studies; Transplantation Conditioning; Vidarabine	2022
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. Blood advances, 2022, 03-22, Volume: 6, Issue:6 Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine	2022
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major. Annals of hematology, 2022, Volume: 101, Issue:3 Topics: Adolescent; Antineoplastic Agents; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Vidarabine	2022
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W Bone marrow transplantation, 2022, Volume: 57, Issue:3 Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2022
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. Oncotarget, 2022, Volume: 13 Topics: Alkylating Agents; AMP-Activated Protein Kinases; Antineoplastic Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Caspase 3; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Nucleosides; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; STAT5 Transcription Factor; Sulfonamides; Transplantation Conditioning; Vidarabine	2022
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis. Transplantation and cellular therapy, 2022, Volume: 28, Issue:6 Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies; Vidarabine	2022
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis. Annals of hematology, 2022, Volume: 101, Issue:6 Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Vidarabine	2022
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. Bone marrow transplantation, 2022, Volume: 57, Issue:6 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine	2022
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma. Bone marrow transplantation, 2022, Volume: 57, Issue:7 Topics: Aged; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Vidarabine	2022
Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning. Transplantation and cellular therapy, 2022, Volume: 28, Issue:7 Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Thiotepa; Vidarabine; Young Adult	2022
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis. Transplantation and cellular therapy, 2022, Volume: 28, Issue:9 Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2022
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities. Bone marrow transplantation, 2022, Volume: 57, Issue:11 Topics: Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine	2022
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study. Transplantation and cellular therapy, 2023, Volume: 29, Issue:1 Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies	2023
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. Bone marrow transplantation, 2023, Volume: 58, Issue:1 Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult	2023
A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study. British journal of haematology, 2023, Volume: 200, Issue:5 Topics: Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Prospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors	2023
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation. Pediatric blood & cancer, 2023, Volume: 70, Issue:2 Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Myelodysplastic Syndromes; Retrospective Studies; Siblings; Transplantation Conditioning; Young Adult	2023
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning. Acta haematologica, 2023, Volume: 146, Issue:1 Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine	2023
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par Bone marrow transplantation, 2023, Volume: 58, Issue:3 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2023
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party American journal of hematology, 2023, Volume: 98, Issue:4 Topics: Acute Disease; Adult; Bone Marrow; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Whole-Body Irradiation	2023
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation. Annals of hematology, 2023, Volume: 102, Issue:3 Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine	2023
Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation. Transplantation and cellular therapy, 2023, Volume: 29, Issue:5 Topics: Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies	2023
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone marrow transplantation, 2023, Volume: 58, Issue:6 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2023
Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders. Pediatric blood & cancer, 2023, Volume: 70, Issue:7 Topics: Anemia, Sickle Cell; Busulfan; Child; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Thiotepa	2023
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. Hematology (Amsterdam, Netherlands), 2023, Volume: 28, Issue:1 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning	2023
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience. Bone marrow transplantation, 2023, Volume: 58, Issue:9 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine	2023
Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Transplantation and cellular therapy, 2023, Volume: 29, Issue:11 Topics: Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes	2023
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplantation and cellular therapy, 2023, Volume: 29, Issue:12 Topics: Busulfan; Graft vs Host Disease; Humans; Methotrexate; Primary Myelofibrosis; Recurrence; Tacrolimus	2023
Determination of Treosulfan and Fludarabine in Plasma by Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry (TFLC-MS/MS). Methods in molecular biology (Clifton, N.J.), 2024, Volume: 2737 Topics: Busulfan; Chromatography, Liquid; Humans; Tandem Mass Spectrometry	2024